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Abstract 
Tumor hypoxia is associated with the malignant progression and tumor responsiveness to 
therapy.  Targeting tumor hypoxia has a profound impact in assessing anti-cancer treatments. 
Previously we reported the use of 2-nitroimidazole and indocyanine green conjugate (2-
nitroimidazole-ICG) to target tumor hypoxia in in vivo tumor models. In this study, we 
evaluated a new generation hypoxia-targeted rigid dye that has a higher fluorescence yield. 
Results show that it has ~100 nm absorption/emission wavelengths shift and 3-4 times 
fluorescence quantum yield comparing with 2-nitroimidazole-ICG, as well as more than twice 
in vivo tumor fluorescence intensity. These initial results suggest that the targeted rigid dye 
may significantly improve in vivo tumor hypoxia targeting. Moreover, relationship between 
hypoxia targeting capability and nitro-linked location was studied. 4-nitroimidazole-
piperazine-indocyanine derivative was synthesized by linking the nitro-group at 4th carbon of 
the imidazole ring. Our in vivo hypoxia targeting of 4-nitroimidazole-ICG showed comparable 
signal to 2-nitroimidazole-ICG, which is consistent with cell and immunohistochemistry 
results. 
We have developed ultrasound (US)-guided diffuse optical tomography (DOT) technique 
to assist US diagnosis of breast cancer and to predict neoadjuvant chemotherapy response of 
breast cancer patients. With the US guidance, diffused light measurements were made at the 
Feifei Zhou – University of Connecticut, [2017] 
 
 
breast lesion site and the normal contralateral reference site with a handheld hybrid probe, and 
the data was used to estimate the background tissue optical properties for imaging 
reconstruction. However, background optical properties were affected by the chest wall 
underneath the breast tissue. Currently, we have analyzed data from 297 female patients and 
results have shown statistical significant correlation between fitted optical properties (µa and 
µs’) and the chest wall depth detected by a boundary detection algorithm applied to co-
registered US images (r > 0.27, p < 1.0 × 10-4). After subtracting background µa at each 
wavelength, the difference of computed total hemoglobin (tHb) between malignant and benign 
lesion groups has improved. Receiver operating characteristic (ROC) curve analysis shows 
significant improvement for predicting early malignant lesion diagnosis after subtraction. For 
early stage malignant lesions, the area-under-the ROC curve (AUC) has improved from 88.5% 
to 91.5%. For all malignant lesions, the AUC has improved from 85.3% to 88.1%.  
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Chapter 1 Introduction 
Minimal or non-invasive cancer detection and diagnosis using optical techniques in the near 
infrared (NIR) range have been extensively studied in the biomedical field. Compared with 
conventional diagnosing techniques such as the magnetic resonance imaging (MRI) and 
computed tomography (CT), optical imaging of early stage tumors is quite promising due to 
its low-cost, high sensitivity and non-radiative characteristics. As biological tissues generally 
have high absorption and scattering optical coefficient which cause a fast attenuation of light 
in the VIS-UV range and therefore impede the optical detection of tumor embedded under skin, 
NIR light is more used for these studies. And the breast, prostate and brain tumors are some 
major subjects of these studies due to their special physical structure appealable for the 
application of optical imaging.  
There are various of methods in terms of in vivo tumor diagnosis using optical techniques. 
Fluorescence imaging and diffuse optical spectroscopy or tomography (DOS or DOT) are two 
methods among them. For the fluorescence tumor imaging, where the signal is generally low 
compared with the excitation, and the fluorescence usually comes from more than one 
fluorophore, a fluorescent probe that specifically target the tumor region can significantly 
increase the signal to noise ratio (SNR), therefore improves the sensitivity and accuracy of 
tumor detection. In the area of diffuse optical spectroscopy or tomography, which is based on 
the diffuse theories of light propagation in tissue, many different systems have been developed 
and proved to be useful for tumor detection, as it will be discussed later in Chapter 4. Currently, 
methods in either algorithm, hardware or data analysis that improve sensitivity, stability and 
accuracy are of most interest to investigate. This thesis is mainly aimed to discuss and report 
different methods we used for improving these two modalities in breast tumor diagnosis, 
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testing methods of these improvements, and the statistical analysis of the improvements with 
either animal or clinical data. 
The structure of this thesis is stated as below: Chapter 1 gives a brief introduction on the 
background of each studies that are discussed later. The topics include: breast cancer status, 
the optical screening of breast cancer, some basic theories in tissue optics, the main cancer 
biomarkers under investigation (including the total hemoglobin (tHb), oxygen saturation (SO2) 
and tumor hypoxia), and then the phantom that mimics breast tissue used for systems 
calibration. Chapter 2 describes the novel fluorescence dyes developed by our collaborator 
Dr. Smith’s lab, for tumor hypoxia labeling. It focuses on the animal tumor studies and tests 
on both rigid dye and piperazine-4-nitroimidazole-ICG dye. For a deeper understanding of the 
hypoxia targeting properties of these dyes, Chapter 3 introduces a biotin dye study with both 
in vivo experiment and excised tumor tissues. Chapter 4 reviews the current existing diffuse 
optical systems used for breast cancer diagnosis, their principles and reported diagnostic results. 
By comparing our DOT system with the ones developed by other groups, we proposed a 
background subtracting method for reducing a problem specifically exists in our DOT system 
or any DOT systems using similar method to ours. Later, a solid statistical analysis of the 
diagnostic improvement using this method with 297 patients’ data was discussed. Chapter 5 
describes a phantom study using hemoglobin for the DOT system calibration and imaging test. 
Chapter 6 is a summary and proposes some future works at the end.  
1.1 Breast cancer 
According to a recent annual cancer status report based on national cancer data through 1975-
2011, breast cancer is the most common cancer for women by a wide margin among all racial 
and ethnic groups in the United States, and is one of the three top leading causes of cancer 
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death for women (the other two are lung and colorectal cancers) [1]. Understanding the cause 
of breast cancer is one of the most important purposes of breast cancer study. 
The reason for cause of breast cancer at the early stage can be a comprehensive 
combination of multiple factors. A major opinion relates breast cancer to the hormone receptor 
expression (HR+/-) and human epidermal growth factor receptor 2 (HER2+/-), which are 
proteins associated with picking up signals that tells cells to grow [1]. According to the report, 
the breast cancer can be categorized as four subtypes: Lumina A (HR+/HER2-), Lumina B 
(HR+/HER2+), HER2-enriched (HR-/HER2+) and triple-negative (HR-/HER2-, also referred 
as basal-like). Additional analysis also showed that the incidence of HR+ breast cancer is much 
higher than the other subtypes, while it is least likely to develop into an invasive breast cancer 
in later stages. Its development is more related with the reproductive factors, including the 
breastfeeding, number of children and age of first birth, etc. Moreover, the basal-like triple-
negative breast cancer is more racial and ethnic related and is more likely to develop into an 
invasive breast cancer [1].  
1.2 Optical screening of breast cancer 
The significance of optical screening in early stage breast cancer has been implied by the 
statistical report that the death rates due to breast cancer among females during 5 years span 
(2007-2011) decreased by 1.9% compared with the 10 years span (2002-2011) data with 
significant p-values, while the incidence of breast cancer remains stable during that time range 
[1]. Moreover, the ranking of mammography use is highest in whites, blacks, API (Asian-
Pacific Islander), and lowest in Hispanics, respectively. It matches the racial/ethnic rankings 
for HR+/HER2- breast cancer incidence rates, meaning more cancers of this type were 
discovered. In addition, HR+/HER2- cancer (which ranges the highest cause of breast cancer) 
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is high in low poverty areas, implying that disparities in access to health services and 
subsequently utilization of cancer screening may contribute to the difference.  
In most of the developed world, screening women for cancer annually for preventing 
disease has become the ‘standard of care’ for women over the age of 50 [2]. However, an 
important challenge remains to reduce the over-diagnosis and not true excess in disease 
occurrence. And still there are populations where this screening program does not work well, 
including: highly ratio-dense breast tissue, known higher risk due to genetic factors, complex 
breast tissue due to previous surgery, and younger women who are within the age range where 
annual screening is recommended. 
To sum up, optical screening is important in discovering the incidence of early stage breast 
cancer, and improving the cure rate of HR+ type breast cancers. And it is also indicated by the 
report that there are spaces for improving the optical screening technique and implementation.  
1.3 Tissue-light interaction 
For optical screening of breast, light passing through the tissue carries information about 
optical properties of the tissue. The beam of light can be viewed as many photons incident 
from the same location with similar direction. When a photon propagates in tissue, it undergoes 
millions of events of scattering, and after those it may disappear due to the absorption of tissue, 
or be reflected or transmitted through the tissue medium. The absorption and scattering 
coefficients (µa and µs) characterize the probability of the occurrence of each event. According 
to tissue optics, µa is associated with absorbers/chromophores in tissue, including the melanin 
in skin, hemoglobin in blood, and some other molecules such as the fluorophore. And µs is 
associated with small particles including the cell membrane, mitochondria, and collagen fibers 
in the extracellular matrix (ECM). 
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Since µa and µs are light wavelength dependent, it always has the advantage in using the 
NIR light with wavelength ranging 700-1000 nm for optical screening of tissues. For the 
chromophores and water in tissue, there is an absorption valley for light 600-1300 nm (the 
optical window, as shown in Fig. 1.1). In this range, the excitation light is absorbed less and 
penetrates deeper than those at shorter or longer wavelengths, meaning the reflective or 
transmitted signal carries information of tissue from deeper location or with larger thickness. 
Although the penetration depth of NIR light in tissue varies by the tissue type, for general 
breast tissue, this falls in several centimeters scale.   
 
Figure 1.1. Optical absorbing spectra of tissue and optical window [3] 
 
1.4 Hemoglobin content and oxygen saturation  
According to part 1.2, it was reported by many studies that the hemoglobin content (including 
oxygenated hemoglobin, HbO2 and de-oxygenized hemoglobin, Hb) and oxygen saturation 
(SO2, defined by the ratio of HbO2 over total hemoglobin) are closely related with tumor 
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development. The hemoglobin generally increases due to angiogenesis for providing more 
nutrition and oxygen to breast tumor for keeping the rapid growing speed. But the SO2 changes 
in a complicated way either due to the irregular vasculature in tumor or fast consumption of 
oxygen by tumor cells. Part of the tumor tissue shows extremely low SO2 when tumor develops 
to the later stages. This poses problems to therapeutic or radiative treatment as drugs are 
delivered to tumor through blood circulation, or radiative agents’ effects depend largely on the 
oxygen concentration. The relationship between total hemoglobin/SO2 and age, menstrual 
cycle effects, menopausal status, pregnancy number, breast density, body mass index (BMI), 
skin color, are also under intensive studies. And the study subjects are not limited to the lesion 
breast, but also the normal contralateral breast.   
In order to estimate the concentrations of hemoglobin, measurements of tissue absorptions 
at more than two wavelengths are needed. More wavelengths measurements lead to more solid 
hemoglobin concentrations solution. Our DOT system used four wavelengths light ranging 
from 740-830 nm as the signal, and the four measured absorption coefficients are to be plugged 
in the equation below to determine the concentration of hemoglobin by least square solution 
[4].  
[
𝜇𝑎𝜆1 
𝜇𝑎𝜆2
𝜇𝑎𝜆3
𝜇𝑎𝜆4
] = 2.303 [
𝜀𝐻𝑏𝑂2𝜆1 𝜀𝐻𝑏𝜆1
𝜀𝐻𝑏𝑂2𝜆2 𝜀𝐻𝑏𝜆2
𝜀𝐻𝑏𝑂2𝜆3 𝜀𝐻𝑏𝜆3
𝜀𝐻𝑏𝑂2𝜆4 𝜀𝐻𝑏𝜆4
] [
𝑐𝐻𝑏𝑂2
𝑐𝐻𝑏
]                                   (1.1) 
Where the 𝜀 is the extinction coefficients for HbO2 and Hb at specific wavelengths, as can be 
found in the known spectra (Fig. 1.2) [4]. 
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Figure 1.2. Hemoglobin extinction coefficients 
 
1.5 Tumor hypoxia and our studied dyes 
Tumor hypoxia mainly appears as a structural or functional misbalance between the tumor 
micro-environmental oxygen supply and consumption, and is associated with the rapid 
progression of malignant tumors [5-8]. Tumor hypoxia is an important target in the assessment 
and prediction of therapy, as it is known to cause the aggressive phenotype and increased 
resistance to therapy [9, 10]. Positron emission tomography (PET) is an established method 
for imaging hypoxia noninvasively [11]. Imidazole compounds are widely used to prepare PET 
radionuclides, and it is known that 2-nitroimidazoles show an affinity for hypoxic cells, with 
the highest electron affinities of this class of compounds [12-16]. Problems associated with 
PET, including the requirement that radioactive tracer must be administered to patients by 
injection, as well as the high system cost, have spurred the development of alternative tumor 
hypoxia imaging techniques.  
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Indocyanine green (ICG) is the only FDA approved fluorescence imaging agent for patient 
use, but its application is hindered by problems such as low quantum yield and quick loss of 
fluorescence after binding to protein in circulating blood [17-19]. The 2-nitroimidazole and 
ICG conjugate using piperazine linker (piperazine-2-nitroimidazole-ICG) was previously 
reported by our our and Dr. Smith’s lab in UConn department of Chemistry to improve tumor 
hypoxia targeting as compared with the first generation 2-nitroimidazole ICG conjugate using 
ethanolamine linker (ethanolamine-2-nitroimidazole-ICG) [20]. Later, based on the hypothesis 
that molecules with more planar and rigid structures have a higher fluorescence yield as they 
could release less absorbed energy through molecular vibration or collision [21, 22], Dr. 
smith’s lab have developed the third generation of 2-nitroimidazole ICG conjugate. This 
conjugate has 2 carbons less in the polyene linker, and is studied and referred as the hypoxia-
targeted rigid dye in the following text [23]. The bis-carboxylic acid referred as non-targeted 
rigid dye was also tested for comparison with hypoxia-targeted rigid dye.  
1.6 Optical and ultrasound phantoms 
Phantoms are the manufactured tissue-simulating objects for purpose of mimicking the 
properties of human or animal tissues [24]. They generally serve as the standard measuring 
target for calibrating new systems and routinely monitoring of existing systems, especially for 
the optical and ultrasonic ones. They are usually generated with the matrix, absorber(s), 
scatterer(s) and/or fluorophore(s). Aqueous suspension or solid phantoms made with agar or 
silicon rubber can be used as the matrix for holding the scatterers, absorbers and/or 
fluorophores. Ink, blood or molecular dyes are generally used as the absorbers. Intralipid (used 
for aqueous suspension), titanium dioxide (TiO2), aluminum oxide (Al2O3) and microspheres 
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can be used as the scatterers [24]. The manufacturing procedures varies, however, eventual 
optical properties are expected to be as close as possible to the study tissues [24]. 
 One method of making a phantom is to directly use the hemoglobin. Hemoglobin is the 
main absorber in red blood cells. Many companies provide products of purified hemoglobin in 
different forms.  It can be filled arbitrary concentration in a clear container or mixed in solid 
mixture to mimic the absorbing target (such as the diseased part) in tissue. Although it’s hard 
to make arbitrary SO2, it is possible to make hemoglobin phantom with SO2 equals close to 0 
and 100%, under extreme conditions. In the study described in this thesis, we added Na2S2O4 
powder to oxygenated-hemoglobin solution to make it de-oxygenated for system calibrations. 
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Chapter 2 Tumor hypoxia targeted fluorescence dyes 
2.1 Introduction 
In the previous work, Nrusingh et al. have demonstrated a noninvasive method for in vivo 
imaging of hypoxic tumors [25]. This method is based on fluorescence NIR imaging of dyes 
in hypoxic tumors, after injection of a nitroimidazole‐indocyanine dicarboxylic acid conjugate, 
henceforth referred to as a dye‐conjugate. In that work, dicarboxylic acid 2 was used as the 
untargeted dye rather than 1, and 2-nitroimidazole was linked to the dye using ethanolamine 
[20, 25] or piperazine [26] linkers as shown in Fig 2.1, which are referred as the hypoxia 
targeting ethanolamine‐dye conjugate 3 and a piperazine‐dye conjugate 4, respectively. 
The first-generation dye conjugate (3) was shown to be a successful candidate for non-
invasive tumor hypoxia mapping using a near-infrared fluorescence imaging technique [20]. 
The fluorescence signals were measured to be two-fold higher at the tumor site, relative to the 
untargeted dye 2 [27]. Immunohistochemistry stains for tumor hypoxia, using 
Hypoxyprobe™-1, showed that hypoxic areas in the tumor correlated with the presence of dye-
conjugate 3.  Furthermore, it was showed that 3 could be detected in the tumor for 5-7 h, post-
injection. The ester linkage in 3 was viewed as too labile and in an effort to improve in vivo 
efficacy the ethanolamine moiety was replaced with a more robust piperazine moiety, 
generating the second-generation dye conjugate 4 [26].  In vivo targeting experiments in mice 
with 4 showed a two-fold higher fluorescence in hypoxic tumors relative to 3, within three h 
of injection, and the florescence was 1.6-1.7 times higher beyond three h [26].  
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Figure 2.1.  Indocyanine dyes (1, 2) and first and second-generation dye conjugates (3 and 4) 
 
Further efforts have focused on the improve of the fluorescent yield of the dye. It is known 
that molecules with more planar and rigid structures have a higher fluorescence yield as they 
release less absorbed energy via molecular vibration or collision [21, 22]. Based on this 
hypothesis, a ring was introduced into the polyene unit of 2 by Dr. Smith’s lab. It was found 
to led to a lower in vitro fluorescent yield, but shortening the polyene chain by two carbon 
atoms (8) led to significant enhancement in the in vitro fluorescence [23]. After that, a third 
generation 2-nitroimidazole ICG conjugate (12) was synthesized from new dye 8, which is the 
hypoxia-targeted rigid dye, as shown in Fig. 2.2. The bis(carboxylic acids) 2 and 8 are referred 
to as non-targeted dyes because they do not have the nitroimidazole moiety associated with 
targeting tumor hypoxia. The goal of this study is to quantify the in vivo hypoxia targeting 
capability of 12 relative to the non-targeted dyes as well as relative to 4, using a murine tumor 
model. A direct comparison of the in vivo performance of the rigid dye-conjugate 12 with the 
second-generation hypoxia-targeting dye (4) showed greatly improved imaging for 12. The  
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Figure 2.2.  Molecular structure of non-targeted rigid dye 8 and targeted rigid dye 12. 
 
bio-distribution of each dye in different organs was also evaluated and compared with the dye 
uptake in the tumor. 
In another study, the relationship between hypoxia targeting capability and the 
nitroimidazole linked location was also studied [28, 29]. Although both 2-nitroimidazoles and 
4-nitroimdazole derivatives have been studied as radiopharmaceuticals in hypoxia, 2-
nitroimidazoles are most commonly used as hypoxia labeling markers since it has a higher 
electron affinity and a higher reduction potential than either 4-nitroimidazole or 5-
nitroimidazole [30]. In addition, the 4-nitroimidazole compounds were shown to be toxic [31]. 
Therefore, the initial works focused on the known affinity of 2-nidtroimidazole compounds for 
tumor hypoxia as a molecular probe. However, the cost of 2-nitroimidazole is nearly 
prohibitive in synthesizing the 2-nitroimidazole dye-conjugates. Based on price considerations 
alone, the preparation of a 4-nitroimidazole dye-conjugate was a worthy goal. Despite the 
concerns about the toxicity of 4-nitroimidazole derivatives, previous work by other groups 
showed that 4-nitroimidazole complexes used for imaging tumor hypoxia was feasible [32].  
In this work, we report at first on the performance of hypoxia targeted rigid dye in 
comparing with the second generation untargeted (2) and targeted ICG dye conjugate (4) [33]. 
After that, we also report the performance of the piperazine-4-nitroimidazole-ICG derivative  
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Figure 2.3. Molecule structure of imidazole ICG (5) and 4-nitroimidazole ICG dye-conjugate 
(6) 
 
6, using the unsubstituted imidazole derivative 5 as a reference (Fig. 2.3). A comparison of the 
hypoxia targeting performance of 6 and 5 in balb/c tumor-bearing female mice, with the 
previously tested piperazine-2-nitroimidazole-ICG dye-conjugate (4), is also discussed. We 
used various techniques to validate our findings in the in vivo experiments. 
2.2 Materials and Methods 
2.2.1 Measurement of quantum yield 
In order to measure the quantum yield of hypoxia-targeted rigid dye 12 and non-targeted rigid 
dye 8, we followed the procedures described in the reference [34]. Any of these four unknown 
samples is measured against a fluorescence standard, Indocyanine green (ICG) from Sigma-
Aldrich with a known quantum yield Φ𝑓 =0.012 [35] with Varian Cary® 50 UV-Vis 
Spectrophotometer and Varian Cary® Eclipse Fluorescence Spectrophotometer. The 
fluorescence quantum yield is then calculated according to eq. 2.1, by taking into account the 
absorbance through the absorption factor 𝑓𝑥(𝜆𝑒𝑥) and the fluorescence through the integral of 
fluorescence  𝐹𝑥(𝜆𝑒𝑚)  at specific excitation wavelength 𝜆𝑒𝑥  and a range of collection 
wavelength band 𝜆𝑒𝑚.  
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Φ𝑓
𝑖 = Φ𝑓
𝑠  𝑓𝑠(𝜆𝑒𝑥)
 𝑓𝑖(𝜆𝑒𝑥)
∫  𝐹𝑖(𝜆𝑒𝑚)𝜆𝑒𝑚
∫  𝐹𝑠(𝜆𝑒𝑚)𝜆𝑒𝑚
     (2.1) 
Here both standard (s) and unknown dye (i) were measured in 9.25% sucrose, thus compared 
with the reference, the difference of refractive indices between standard and unknown dye can 
be ignored. The excitation/collection wavelengths are shown in Fig. 2.4. 
2.2.2 Murine tumor model and imaging 
6-8 weeks old balb/c mice with body weight around 20g were used in this study and 
transplanted with 4T1 tumor cells. The experiments were performed when the tumor size had 
attained a diameter of 5 mm or greater, 10-15 days post-inoculation.  Mice with a tumor bared 
on the top of their right legs were imaged with an IVIS® Lumina II Imaging System (Caliper 
Life Sciences, Hopkinton, MA) [36]. 
Mice were separated into four groups with similar average tumor size. Each group of mice 
was injected, via retroorbital injection, with 100 µl of either biscarboxylic acid ICG (2), 
piperazine-2-nitroimidazole-ICG (4), non-targeted rigid dye (8), or hypoxia-targeted rigid dye 
(12) at a concentration of 25 µM. 
Imaging the tumors began 1 minute post-injection and were repeated at 5 min, 15 min, 30 
min, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 24 and 48 h.  In all cases, the in vivo fluorescence intensity was 
quantified. After 48 h, the tumor tissue was excised from each sacrificed mouse, and 
immediately frozen in the liquid nitrogen. After acquiring florescence images, the tissues were 
stored in the -80 °C freezer for later histology processing. 
2.2.3 Immunohistochemistry 
To visualize the hypoxic area in the tumor samples by immunohistochemistry (IHC), the 
Hypoxyprobe™1 plus kit, which contains the 2-nitroimidazole derivative pimonidazole 
hydrochloride [1-(2-nitro-1H-imidazol-1-yl)-3-(piperidin-1-yl)propan-2-ol] was purchased 
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from HPI, Inc. (Burlington, Massachusetts, USA).  A total of 60 mg of pimonidazole 
hydrochloride per kg body weight, diluted in 0.9% saline solution was injected intravenously 
into mice 30-45 minutes before sacrificing. Immediately after the animals were euthanized, the 
tumor specimens were collected and flash-frozen in the liquid nitrogen, and subsequently 
sectioned into 16 μm sections on a Leica CM 3050S cryotome (Leica, Nussloch, Germany). 
The prepared tumor sections (sample number: 8 for hypoxia-targeted rigid dye, 12 for non-
targeted rigid dye) were stored in -80 °C before staining. After thawing, the sections were fixed 
in cold acetone for 10 minutes, and later rinsed and incubated overnight at 4 °C with FITC-
Mab1 diluted 1:20 in PBS containing 0.1% bovine serum albumin and 0.1% Tween 20.  
The hypoxic areas were visible with FITC attaching to pimonidazole hydrochloride under 
the fluorescence microscope (Zeiss Axio M2, Pennsylvania, USA). In order to analyze the 
targeting property of 12 in tumor, fluorescence images are acquired simultaneously with filter 
sets for channel 1- Cy5 and channel 2- FITC. The absorption and emission peaks of Cy5 
(650/670 nm respectively) are overlapped with that of 12 and 8. Digital images of the whole 
tissue slices were scanned and acquired with 2.5× and 10× objective magnifications. For 10× 
magnification, the exposure time is used as 1200 ms for channel 1 and 250 ms for channel 2. 
Obtained digital images were transferred to ImageJ software, delineated with the boundaries 
of hypoxic areas, split by channels for separate analysis. Each image is later imported to Matlab, 
converted into a binary image with a threshold of 12% of the labelled tissue area, and used for 
computing the correlation of the labelled areas between pimonidazole hydrochloride and the 
rigid dye (12 or 8). 
For the 4-nitroimidazole dye study, comparison was also made with the labeled areas on 
tumor tissue sections stained with the Hypoxyprobe™-1 probe and our dyes (dye 4, 5 and 6). 
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As the excitation and collection wavelengths for dye 4, 5 and 6 are in the 700-800 nm range 
and cannot be imaged with regular fluorescence microscope, we used the Odyssey Infrared 
imaging system (Li-Cor Bioscience, Nebraska) to image the residues of our dyes. The system 
provides two excitation wavelengths (660 nm and 780 nm) and resolution ranging 21 to 339 
µm. For this study, we chose the 780 nm excitation channel and scanning resolution at 21 µm. 
Other parameters were set as: focus offset, 0.5mm; intensity, 5.0; quality, high. After the 
images were acquired, the average of integrated intensity was computed and a comparison was 
made among dye 4, 5 and 6. 
2.2.4 Hypoxia versus normoxia cell experiments (for the 4-nitroimidazole dye study) 
Hypoxia-dependent targeting of the dye was assessed using 4T1 breast cancer cells. Twelve 
dishes (T7425-2, 60 x 15 mm, BD Falcon, NJ, USA), with approximately 1 million 4T1 cells 
each were evaluated. One group of six dishes was exposed to hypoxic conditions (5% CO2, 1% 
O2, 94% N2, 37°C) by passing the gas mixture (5 psi at room temperature) into a hypoxic 
chamber (Billups-Rothenberg Inc, CA, USA) for 10 min. The gas mixture was provided by 
Airgas East (Cheshire, Connecticut). The chamber was then sealed and incubated for 15 h. The 
second group of six dishes was incubated under normoxic conditions (5% CO2, 95% O2, 37°C) 
for the same period. Two dishes of each groups were treated with 3 ml of either 6, 4, or 5 at 15 
μM. Then the hypoxic group was put back into the hypoxic chamber and re-incubated both for 
9 h. The medium was then removed and dishes were rinsed with PBS and immediately taken 
for imaging using the Lumina II Imaging System. 
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2.3 Results 
2.3.1 In vitro measurements of rigid dyes 
The optical properties of 12 were measured and the normalized spectra are displayed in Fig. 
2.4. It shows that in measuring the quantum yield with the standard dye of ICG from Sigma-
Aldrich, the excitation was performed at 640 nm, as labeled with arrows. The fluorescence was 
collected from 650-900 nm for all dyes. Six concentrations of each dye were measured for the 
calculation of quantum yield. All dyes are measured with spectrometer gain set at medium and 
the measurements are performed in 9.25% sucrose. The spectra of non-targeted rigid dye 8 is 
similar to that of 12. The spectra peak wavelengths of biscarboxylic acid ICG 2 and piperazine-
2-nitroimidazole-ICG 4 are also similar, as can be referred to the past report [26]. The 
absorption maximum for 12 was at 657 nm and the emission maximum was at 670 nm, a shift 
of around 100 nm and 110 nm for absorption and emission, respectively, when compared with 
4. The other measured optical properties for non-targeted rigid dye 8 and hypoxia-targeted 
rigid dye 12 in 9.25% sucrose solvent are shown in Table 2.1.  
 
Figure 2.4. Normalized absorption (solid curves) and fluorescence (dash curves) spectra of 
hypoxia-targeted rigid dye 12 (black) and ICG from Sigma-Aldrich 1 (gray). 
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Table 2.1. The optical properties of rigid dyes in 9.25% sucrose solution 
Compound 𝝀𝒂𝒃𝒔
𝒎𝒂𝒙(𝒏𝒎) 𝝀𝒆𝒎𝒔
𝒎𝒂𝒙(𝒏𝒎) Extinction coefficient 
𝜺 (M-1cm-1) 
Quantum 
yield (𝚽) 
Non-targeted 
rigid dye 8 
657 671 261,971 0.403 
Hypoxia-targeted 
rigid dye 12 
657 669 268,006 0.467 
 
2.3.2 The in vivo distribution of the Dye-Conjugate as a function of time   
Fig. 2.5 shows a typical set of fluorescent images obtained by IVIS Lumina II Imaging System 
over a 48-hour period for a mouse injected with 100 µl of biscarboxylic acid ICG 2 (a), 
piperazine-2-nitroimidazole-ICG 4 (b), non-targeted rigid dye 8 (c) and hypoxia-targeted rigid 
dye 12 (d) at 25 µM concentration. The first row shows fluorescent images obtained by IVIS 
Lumina II Imaging System using a 710±15 nm/810-875 nm excitation/collection filter pair 
over a 48 h period for individual mouse injected with 100 µl of (a) biscarboxylic acid ICG 2; 
(b) piperazine-2-nitroimidazole-ICG 4 at 25 µM.  The second row shows fluorescent images 
using a 640±15 nm/695-770 nm excitation/collection filter pair over a 48 h period for 
individual mouse injected with 100 µl of (c) non-targeted rigid dye 8 and (d) targeted rigid dye 
12 at 25 µM. The tumor area for each case was labelled with red circles when the tumor  
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Figure 2.5. Typical sets of fluorescent images as a function of time injected with dye 2 (a), 4 
(b), 8 (c) and 12 (d) at 25 µM. 
 
fluorescence intensity reaches to the peak at around 15 min post-injection. All dyes were 
accumulated in and cleared from the tumor area with visible and different washout rates, 
reflecting tracer-specific uptake mechanisms. The improvement on the fluorescence intensity 
of dye 12 accumulated in the tumor region and longer washout time compared with the other 
dyes are visible from Fig. 2.5. 
2.3.3 Dye washout characteristics 
The washout curves of each dye in tumor area were averaged at each observation point, and 
the bar plot with STD for washout period is shown in Fig. 2.6.  All tracers were injected at 25 
µM concentration. It is shown that for 12 the fluorescence intensity reached an average 
maximum of 8.0×109 (Radiant efficiency, unit: p/sec/cm2/sr/(µW/cm2)) in 5-15 min post-
injection and the signal remained above detection level (2×108, decided by background 
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fluorescence) in 48 h. For 8, the fluorescence reached an average maximum of 7.0×109 in 5-
15 min post-injection and the signal remained above detection level in 10 h. The fluorescence 
for 4 reached its average maximum intensity of 3.5×109 at 15 min and the signal remained 
above detection level in 10 h. For 2, fluorescence intensity reached lower average maximum 
of 1.5×109 approximately at 15 min and then the signal was decreased below detection level 
by around three h post-injection. 
 Two-sided student’s t-test was performed between average values of 12 and 8, 12 and 4, 
12 and 2 in the 2-48 h window and results show statistically significance between each pair 
(Fig. 2.6).  Within the 2-48 h time window, the average tumor uptake of the hypoxia-targeted 
rigid dye (12) is 2.7 times that of the non-targeted rigid dye (8), 1.9 times that of the piperazine-
2-nitroimidazole-ICG (4), and 7.2 times that of the biscarboxylic acid ICG (2). 
 
Figure 2.6. Kinetics of tumor uptake and washout characteristics of 12, 8, 4 and 2. 
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2.3.4 Dye residue in tumor after 48 hours   
All mice were sacrificed after 48 h post-injection. Tumor tissue were excised and imaged in 
the same imaging condition (Fig. 2.7). For mice injected with 2, an average maximum 
fluorescence intensity of 0.4×108 was detected in the tumor. For mice injected with 4 and 8, 
higher averaged maximum fluorescence intensity of 1.5×108 and 2.2×108, respectively, were 
detected in the tumor.  The highest averaged maximum fluorescence intensity of tumor was in 
the group injected with the 12, measured as 5.0×108.  
Based on the ex vivo distribution study, the 48 h tumor uptake of the hypoxia-targeted rigid 
dye (12) is about 2.3 times that of the non-targeted rigid dye (8), 3.4 times that of the 
piperazine-2-nitroimidazole-ICG (4), and 14 times that of the biscarboxylic acid ICG (2). The 
two-sided student’s t-test on the ex vivo tumor radiant efficiency data between hypoxia-
targeted (12) and non-targeted rigid dye (8) is statistical significant (p=0.004).  
 By comparing the fluorescence radiant efficiency of the dye in vivo at 48 h post-injection 
(Fig. 2.6) and radiant efficiency of the ex vivo samples (Fig. 2.7), we observed similar or higher 
fluorescence intensity in the latter (in vivo: 5.3×108, 1.3×108, 9.7×107, 2.5×107 versus ex vivo: 
5.0×108, 2.2×108, 1.5×108, 3.5×107, for each dye respectively). Since the ex vivo tumor 
imaging was performed on excised tumor without skin, it is reasonable to expect that the 
measured dye fluorescence intensity is similar or higher.    
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Figure 2.7. Ex vivo experimental results. (a) Fluorescence images of excised organs from 
tumor bearing mouse injected with (from left to right): 12, 8, 4, and 2. (b) Statistical results 
in different groups of mice tumor.  
 
2.3.5 Immunohistochemistry (IHC) and dual labeling results 
Typical fluorescence images labelled with pimonidazole hydrochloride-FITC (green, channel 
2) and with hypoxia-targeted dye 12 and non-targeted rigid dye 8 (red, channel 1), are shown 
in Fig. 2.8 top and middle row respectively.  The targeted rigid dye 12 labelled area is mainly 
located in the center region and correlates with the region labelled with pimonidazole 
hydrochloride-FITC; while the non-targeted dye 8 labelled regions are scattered and showed 
no significant overlap with the region labelled with pimonidazole hydrochloride. On average, 
the correlation coefficient between channel 1 and channel 2 images of 12 and 8 is statistically 
significant (p<0.05) as shown in Fig. 2.8 (g). 
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Figure 2.8. IHC results. Top row: (a) Typical overlaid fluorescence image labelled by hypoxia-
targeted rigid dye 12 (red) and commercial lpimonidazole hydrochloride (green). (b) Binary 
image acquired through microscope channel 1 (Cy5) after processing with 11-12% threshold. 
(c) Binary image acquired through microscope channel 2 (FITC) after processing.  Middle 
row: (d) Typical overlaid fluorescence image labelled by non-targeted rigid dye 8 (red) and 
pimonidazole hydrochloride (green). (e) Binary image acquired through microscope channel 
1 (Cy5) after processing. (f) Binary image acquired through microscope channel 2 (FITC) 
after processing. The scale bars in (a) and (d) indicate 1 mm. Bottom row: (g) Correlation 
coefficients computed between Ch1 and Ch2 binary images (hypoxia-targeted rigid dye n=12, 
non-targeted rigid dye n=8). 
 
2.3.6 4-nitroimidazole dye testing results 
The absorption and fluorescence spectra for piperazine-4-nitroimidazole-ICG dye-conjugate 
(6) were also determined using a Varian Cary 50 UV-Vis spectrophotometer. It shows dye 6 
having a maximum absorption peak of 755 nm and emission peak at 790 nm. 
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Figure 2.9. Average fluorescent radiant efficiency of the hypoxic and normoxic dishes of 4T1 
breast cancer cells treated with 5, 4, and 6 [28]. 
 
Based on the in vitro cell experimental results, Fig. 2.9 shows the average radiant efficiency 
of the hypoxic dishes treated with imidazole-ICG 5, piperazine-2-nitroimidazole-ICG 4, and 
piperazine-4-nitroimidazole-ICG 6. A slightly higher fluorescence yield (about 1.1-fold 
increase) was detected for the dishes injected with 6 compared with 4 under hypoxic conditions 
and a 2-fold increase when compared with 5. 
Fig. 2.10 shows the in vivo fluorescence distribution of a mouse injected with 100 µL at 25 
µM concentration of dye 6, 4, and 5 over 48 hours. It shows a rapid uptake of the dye-conjugate 
in the tumor, as well as widespread distribution in the mouse. Washout is rapid in each case, 
but both 4 and 6 are retained in the tumor for a prolonged time relative to 5. Based on the 
evaluation of quantitative dye change as a function of time, the fluorescent intensity for 6 is 
higher with an uptake of about 1.5-fold increase compared to 4, and about 2.5-fold higher than 
5 at the 15 min peak post-injection. Strong fluorescence intensity was still detected three h 
post-injection of 6, which corresponded to about a 1.3-fold increase over 4, and a 1.6-fold  
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Figure 2.10. Average maximum radiant efficiency change in tumor injected with piperazine-
2-nitroimidazole-ICG 4, imidazole-ICG 5, and piperazine-4-nitroimidazole-ICG 6 [28]. 
 
increase over 5. At 48 h post injection, 6 was detected at a similar rate as 4, and both were 
measured at about 11 times higher than the background. The difference of tumor fluorescence 
intensity averaged over 0-48 h period between the 6 and 4 show no significant difference 
(p=0.29) and significant difference between 6 and 5 (p=0.03).  
Fig 2.11 shows the average hypoxic area percentage analyzed with stained tumor sections 
from mice treated with 4, 6, and 5, by IHC method. Our results show no statistically significant 
difference of hypoxic area percentage between the 6 and 4 (p=0.35), and between 6 and 5 
(p=0.87).  
Fig. 2.12 shows the average integrated fluorescence density over the tumor sample area 
injected with dye 4, 6, and 5. These results indicate similar fluorescence properties for both 6 
and 4. The difference of tumor-integrated density between 6 and 4 was not statistically 
significant (p=0.62). However, significant difference was observed between 6 and 5 
(p=0.0001).   
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Figure 2.11. Averaged hypoxic area percentage calculated on all IHC stained tumor slices 
[28]. 
 
 
Figure 2.12. Comparison of average integrated fluorescence intensity calculated with Li-
COR images of mice tumor sections injected with 4, 6, and 5 [28]. 
 
2.4 Discussion and conclusion 
As anticipated, our results show that higher fluorescence intensity is achieved with rigid dye 
12 as compared with the second generation dye 4, although the absorption/emission 
wavelengths shifted ~100 nm from the second generation dye: from 755/780 nm to 657/670 
nm (see Fig. 2.4).  The fluorescence quantum yield of rigid dyes was measured to be about 0.4, 
which is around 5 times higher than that of the second-generation dyes. We believe that the 
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reason for the spectrum shift and quantum yield increase of the rigid dye 8 and the dye-
conjugate 12 is due to the more rigid structure of the polyene chain, but the specific structural 
feature that correlates with these changes is unknown at this time [23]. 
 Ex vivo florescence images of the sliced tumor tissue indicate that the dye molecules were 
not only distributed in tumor periphery area, but also penetrated throughout the entire tumor. 
Although the specific molecules this probe is binding to are yet to be investigated, from the 
report of other 2-nitroimidazole conjugated dye studies [37], we anticipate that this finding is 
due to the presence of nitroimidazole moiety. It is known that 2-nitroimidazole derivatives are 
trapped in the cells under hypoxic conditions, and our results are consistent with similar 
behavior for 4 and 12.  
 Despite the high retention of piperazine-2-nitroimidazole-linked dyes 4 and 12 in the tumor 
region, results also show higher fluorescence intensity in the kidney and liver 48 h post-
injection. In general, as reported by previous references that the 2-nitroimidazoles bind to rats 
liver in the hypoxia region [38], we believe this should be due to the hypoxia targeting of 2-
nitroimidazoles. And moreover, as we observed concentrated fluorescence dye contained in 
the mice urine, and some reports indicated that ICG was selectively bound to the liver, later 
excreted in the bile due to its binding with serum proteins and then eliminated by giving bile 
to the feces [39, 40]. We therefore expect that this soluble dye conjugate is mainly washed out 
through the kidney and also removed through liver and gall bladder, and the binding of our dye 
to these two organs might be partially resulted from this reason. Although during the 
experiment, no observable difference was found for the mice injected with dye 2, 4, 5, 6, 8 or 
12, based on post-injection activity or weight loss, suggesting that there is no significant short-
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term toxicity with the mice injected, more studies are needed to confirm and exploit our 
understanding on the binding mechanisms behind. 
The correlation between the dual-channel labelled images was performed after applying a 
threshold to binary images. By varying the threshold from 8-20%, we found that a lower 
threshold can cause a large variation among tumor samples due to noise. The best threshold 
was found to be 11-12%.  
Lastly, it was demonstrated in the results that the efficacy of 4-nitroimidazole-ICG (6) as 
a hypoxia targeting fluorescence probe. In vitro cell study and in vivo studies showed both 6 
and 4 dye-conjugates retained to a great extent in hypoxic tumors when compared with 
imidazole derivative 5. The Li-COR imaging and IHC results confirmed similar fluorescence 
properties between 6 and 4. Further studies are required to illuminate the retention of 5 in the 
tumors. Future study may focus on toxicity of 6, though no short-term toxicity issue was 
observed. 
In summary, we evaluated the new generation hypoxia-targeted rigid dye that has a higher 
fluorescence quantum yield. Results show more than twice in vivo tumor fluorescence intensity 
comparing with 2-nitroimidazole-ICG. We have also demonstrated comparable hypoxia 
targeting performance of 6 and 4 and better than the imidazole derivative 5. Our initial data 
suggests 6 is applicable as a hypoxia probe with significant cost reduction in synthesis. 
Retention of 5 in tumors suggests possible other factors for its uptake by the tumor.  
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Chapter 3 Toward mechanism of our dye binding: the biotin dye study 
3.1 Introduction 
In the previous studies, we did extensive experiments to systematically investigate the 
performance of our three generations of indocyanine-dye conjugates on the fluorescence 
labeling of tumor cells. Almost all the results from in vitro cell studies, in vivo mice experiment 
and ex vivo tissue investigation suggested our dyes with the 2-nitroimidazole moiety remains 
in the tumor tissue significantly more than the dyes without the 2-nitro or 2-nitroimidazole 
moiety (Figs. 2.5, 2.6, 2.7, 2.8, 2.10 and 2.12). Further, from the in vitro cell studies, the 
binding of dyes with 2-nitroimidazole moiety to the tumor cells is observably higher in hypoxia 
condition than normoxic condition (Fig. 2.9). Moreover, the commercial Hypoxyprobe™-1 
stained areas on the ex vivo tumor tissue slides and our 2-nitroimidazole-dye stained areas are 
generally overlapped with each other (Fig. 2.8 (a)-(c)). But there is little direct proof form our 
results that our 2-nitroimidazole-dyes bind to tumor hypoxia and we do not know to which 
molecule(s) these dyes bind to. Also, we need explanation on the dye residues in other organs 
such as kidney and liver. Is it also mainly due to the hypoxia? With these questions, we 
continued our study with a biotin-linked 2-nitroimidazole dye for obtaining deeper 
understanding on the mechanism. 
A literature review shows that the 2-nitroimidazoles and its binding to the hypoxia tissues 
have been studied for long in the biochemistry field, and many information are given by their 
reported results. An early report in 1976 by Varghese et al. showed that the 2-nitroimidazoles 
bind to hypoxia cells in vitro and in vivo [41]. According to another in vivo experiment, the 
binding of 2-nitroimidazoles to the acid-insoluble fractions of EMT6 tumors in balb/c mice 
amounts to be 2% of the radioactively labeled misonidazole (one derivative of 2-
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nitroimidazoles, as shown in Fig. 3.2 Ia) injected into mice [42]. By combining the previous 
study report that one-half of the 2-nitroimidazole moiety excreted unchanged [43], 
approximately 4% of the metabolized 2-nitroimidazoles was bound to tumor cell 
macromolecules [44]. In the 1980s, Raleigh et al. did an in vivo experiment with the CCI-103F 
(a radioactivity marked 2-nitroimidazole), and showed the NMR signal from CCI-103F in liver 
is 3-4 times that of tumor [45]. 
Many studies of the 2-nitroimidazoles focused on confirming the marking area in tissue is 
the hypoxia area in tumor and normal tissues. Van Os-Corby et al. [46] studied with radiatively 
marked misonidazole and reported that the binding rates and the oxygen concentration for half-
maximum binding of misonidazole to liver tissue was not significantly different from that for 
brain, heart and tumor tissues. In further step, Cline et al. used IHC technique and showed the 
binding of 2-nitroimidazole marker to the hypoxia area occurring in the cytoplasm of canine 
tissues cells, and the binding occurs 10-12 cell diameters away from the tumor blood vessel 
(Fig. 3.1) [47].  
                    
Figure 3.1. Immunoperoxidase labeled section of excised canine mast cell tumor after in vivo 
labeling with CCI-103F. Left, bar = 250 µM and right (the magnified image), bar = 50 µM. 
The black arrows indicate blood vessel location. [47] 
 
For studying the mechanism, Miller et al. and Raleigh et al. did some in vitro experiments 
and indicated that the primary binding is to the proteins[44, 48] with both the side chain and 
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imidazole ring involved, although the consumption of 2-nitroimidazoles may follow various 
pathways [49]. Later, Raleigh et al. [44] found that the binding of reductive 2-nitroimidazoles 
was most efficient to the protein whose disulfides have been reduced to the thiol groups, or 
peptides with the thiol groups such as glutathione and cysteine. In their study, they used 
chemical procedures by adding the 2-nitroimidazoles (tritium of Misonidazoles, Fig. 3.2 Ia, 
and CCI-103F, Fig. 3.2 Ib) into solutions containing the bovine serum albumin (BSA) which 
has disulfides, phosphate buffer and sodium formate and put under hypoxia condition. They 
induced the 2-nitroimidazoles reductive activation and binding by radiation, then detected the 
thiol content (with Ellman’s reagent detected at 410 nm) and 2-nitroimidazoles binding with 
BSA (by detecting the Misonidazoles at 320 nm and by scintillation counting of CCI-103F). 
Results showed protein thiol formation increased sharply just at the point where increased 
binding occurred, and the thiol groups binding to 2-nitroimidazoles are more than twenty times 
more effective than other proteins or nucleophilic groups. By comparing their results with 
previous reports, they formulated the mechanism by which the reductively-activated 2-
nitroimidazoles bind to macromolecules in hypoxia cells, as shown in Fig. 3.2. The 2-
nitroimidazoles are first reduced under hypoxia condition to the form of chemical II in Fig. 3.2, 
and then bind to the protein with thiol group (IIIa and IIIb), at 4 or 5 positions of the imidazole 
ring of reductively-activated 2-nitroimidazoles), or form reversible hydrolyted compount (IV) 
with peptides such as lysine and arginine. Their results showed around 20% of the consumed 
2-nitroimidazoles are bound through path III, and path VI (accounts for 38% of the consumed 
2-nitroimidazoles) is related to the toxicity of the reduced 2-nitroimidazoles. At the end, they 
mentioned that a complete understanding of the mechanism(s) of binding would require that 
the structure of the protein adducts be determined. 
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Figure 3.2. Major pathway of reductive 2-nitroimidazoles and binding to macromolecules 
[44]. 
 
In a later paper, Arteel et. al [38] studied the pimonidazole (one derivative of the 2-
nitroimidazoles) binding to rats hypoxia liver by looking at the binding area with oxygen 
perfused anterograde or retrograde direction, and Gavon et al. [50] studied by regulating liver 
oxygen tension with KCN treatment (can inhibit mitochondrial respiration, thus leads to 
hypoxia). They both used IHC method for the detection of liver tissue pimonidazole-protein 
binding. They showed the pimonidazole binding to the hypoxia proteins is regulated directly 
by the O2 concentration and gave a completed mechanism of this binding, as displayed in Fig. 
3.3. With adequate oxygen, the pimonidazole can be oxidized by catalyst (cytochrome P-450) 
to pimanidazole N-oxide (Fig. 3.3A), or form conjugate by glucuronyl- or sulfo- transferase 
(GT or ST in Fig. 3.3B). It can also get electron from NADH (Nicotinamide adenine 
dinucleotide, a reducing agent) or NADPH (Nicotinamide adenine dinucleotide phosphate, a 
reducing agent) to form the radical intermediate (Fig. 3.3C) and be re-oxidized by the oxygen. 
However, in the hypoxia condition it is further reduced to the hydroxylamine intermediate (Fig. 
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3.3D) and binds to any macromolecules (proteins, peptides and amino acids) that contains the 
thiol group (-SH) (Fig. 3.3F). They concluded by that the binding of reductive pimanidazole is 
not dependent on the pyridine nucleotide redox state (NADH or NADPH concentration), but 
dependent on the micro-environment oxygen concentration, so the binding reflects low oxygen 
in liver cells and is valid technique for quantifying hypoxia in liver tissue. 
Based on our review, the binding is towards the macromolecules (proteins, peptides and 
amino acids) with thiol groups in hypoxia cells in a non-reversible direction. As the thiol group 
is not limited to certain type of protein, the binding should not target only one protein or peptide. 
The critical step for solving our questions mentioned at the beginning of this chapter is to 
identify the proteins that are bound by our 2-nitroimidazole dyes. From the previous study, we 
had one time result from protein analysis with tumor extract showing one fluorescent band by 
gel electrophoresis, which means one group of proteins were found with our 2-nitroimidazole-
ICG dye-conjugate bound. In order to further identify the protein type, Dr. Smith’s lab has 
synthesized the biotin dye with one of the two arms of the 2-nitroimidazole substituted by the 
biotin moiety. Theoretically, by using the specific reaction of avidin-biotin, the protein binding 
to the biotin dye can be separated for later identifying. A half-loaded dye with only one arm 
linked with the piperazine-2-nitroimidazole moiety was also synthesized for comparison. 
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Figure 3.3. Schematic representation of metabolism of pimonidazole in tissue [50]. 
 
 
      
Figure 3.4. Molecular structure of the half-loaded dye and biotin dye 
 
 35 
 
3.2 Methods 
We studied the in vivo fluorescence signal in tumor by injecting the biotin dye into the mice 
and compared with dicarboxylic acid ICG (Fig. 2.1, dye 2), piperazine-2-nitroimidazole ICG 
(Fig. 2.1, dye 4) and the half-loaded dye (Fig. 3.3 left). Following similar procedures as in 
Chapter 2, mice were monitored after the injection of 100 µl dye 2 (n=4), half-loaded dye (n=2), 
dye 4 (n=3) and the biotin dye (n=2) at 25 µM concentration. The tumor was excised from 
mice immediately after sacrificing the mice 48 h after dye injection. And the tissue samples 
were fresh frozen with liquid nitrogen and saved at -80°C.  
Later experiments (cell lysis and protein analysis) are mainly carried out by our 
collaborator Dr. Yao’s group in UConn department of Chemistry. Currently two ongoing 
experiments are performed. In the first one, tumor tissues are blended to get extract with water-
soluble proteins. The mixture (cell fragments with buffering solution) were then centrifuged 
and the supernatant were taken out for the SDS-PAGE analysis. The SDS-PAGE (sodium 
dodecyl sulfate polyacrylamide gel electrophoresis, a western blot method) method is used to 
examine the existence of 2-nitroimidazole bound proteins by electrophoresis using the 
polyacrylamide gel as a support medium. In the second one, part of the supernatant was passed 
through the advin-enriched column, through which the dye-protein complex is separated and 
purified. Then the bound complex is washed down and analyzed again with the SDS-PAGE 
method, and to be imaged to identify the targeted protein molecules. 
After processing, the SDS-PAGE gel with protein loaded was imaged using the Odyssey 
Infrared imaging system (Li-Cor imager), as described in part 2.2.3. This work was done by 
another member from our lab. Comparison was made among mice tumors injected with 
piperazine-2-nitroimidazole ICG, biotin dye and the control (without injecting any dye). Note 
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that as the first round test with mice injected at 25 µM dye concentration did not show 
promising result due to the weak signal that can be barely acquired by the Li-Cor imager, for 
later analysis we increased injection concentration to 50 µM. 
3.3 Results and Discussion 
The optical absorption and emission peaks as well as the extinction coefficient of the biotin 
dye and half-loaded ICG were measured and listed with previous measurements in Table 3.1 
[26]. The absorption and fluorescence emission peaks appear to be similar to those of the ICG 
dyes and are about 100 nm longer than the rigid dye, while the extinction coefficient is close 
to half of the bis-carboxylic acid ICG and pip-2nitroimidazole ICG and close to two-third of 
that of the half-loaded ICG, which might be related to the increased molecule size. 
Table 3.1 Optical properties of the biotin dye in comparison with the previous dyes 
Compound λabs (nm) λem (nm) Extinction 
coefficient (M-1cm-1) 
Bis-carboxylic acid ICG 755 790 221,000 
Half-loaded ICG 755 790 170,994 
Biotin dye 755 785 102,000 
Pip-2nitroimidazle ICG  753 790 230,000 
 
A quantitative comparison of in vivo tumor fluorescence intensity is shown in Fig. 3.5. 
From the result, the in vivo tumor fluorescence intensity reaches its peak at 5-15 min post-
injection, and is quickly washed out after the peak. The average tumor signal in 1-60 min time 
range for biotin dye injection is the lowest compared with other ICG dyes, which might be 
explained by the combined effect of the dye’s optical property and diffusing to the tumor tissue. 
After 60 min, the signal from biotin dye is similar with that of the half-loaded dye, less than  
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Figure 3.5. Tumor fluorescence intensity change over time with four dyes injected.  
 
Figure 3.6. Ex vivo tumor and organs fluorescence intensity with four dyes injected. 
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the piperazine-2nitroimidazole ICG, but higher than the bis-carboxylic acid ICG, which might 
be explained by the effect of hypoxia targeting by the single arm of 2-nitroimidazole link. 
The ex vivo fluorescence images from different organs after being excised form the 
sacrificed mice were also acquired, and a quantitative signal intensity plot of the averaged data 
from different groups were shown in Fig. 3.6. The excised tumor signal is a little different from 
the in vivo tumor signal at 48 H (as shown in Fig. 3.5), in that the fluorescent signal for biotin 
dye is the lowest and similar to the bis-carboxylic one. The strongest signal still comes from 
the kidney, and then from the liver and tumor. 
The Li-Cor imaging results with 50 µM dyes injected are shown in Fig. 3.7. Current results 
show fluorescence coming from one band (as indicated by arrow) in the SDS-PAGE gel loaded 
with mice tumor proteins for mice injected with the biotin dye and piperazine-2-nitroimidazole 
ICG, but not in the control columns. Fluorescence intensity from piperazine-2-nitroimidazole 
injected mice is shown similar to that from the biotin dye injected ones. These bands existed 
only in the gel for tumors with dye injected indicate the existence of proteins that bind to the 
biotin or piperazine-2-nitroimidazole dye. 
 
Figure 3.7. Tumor extract fluorescence image 
 39 
 
3.4 Conclusion  
The optical properties of the biotin dye and half-loaded dye were measured. The in vivo and 
ex vivo test with dye injected mice tumors shows lower signal coming from the biotin dye 
compared with the piperazine-2-nitroimidazole ICG, which may be explained as the effect of 
one arm linked with the 2-nitroimidazole moiety. The fluorescent bands in SDS-PAGE gel 
loaded with proteins extracted from tumor injected with the biotin and piperazine-2-
nitroimidazole dyes suggest a promising way of identifications of exact proteins bound by our 
dyes. Further steps are need to be taking to identify exact bound proteins. 
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Chapter 4 Improving breast cancer diagnosis by reducing chest wall effect in ultrasound 
guide diffuse optical tomography  
4.1 Introduction 
4.1.1 DOT systems 
The diffuse optical spectroscopy or tomography (DOS or DOT) are used to measure the optical 
properties of biological tissue by using diffuse light, whose light rays propagate at different 
angles after interacting with tissues. This technique is based on the diffusive theory to relate 
changes in tissue optical properties to the diffuse light change. High sensitivity, safety and low 
cost are among the most significant advantages compared with the conventional techniques. 
They are also able to provide functional image or information of investigated tissues [51]. In 
current clinical study, human joint, brain, breast and prostate are among the most studied 
subjects for DOS/DOT, as they don’t require too deep penetration of light in these structures. 
 In a DOS system, a measurement can be simply taken with a light source and a detector 
placed on the surface of investigated tissue. According to diffusive theory, properties of a 
homogeneous medium can be decided by measurements taken at two relative source-detector 
locations. In a DOT system, where the optical property images are generated, a couple of 
sources and detectors are used at different geometries. The spatial resolution is limited 
(suggested 5:1 for tissue thickness relative to detectable anomaly size in diffuse imaging) due 
to the ill-posed problem [51]. Increasing the number of source and detector pairs can remedy 
this problem, but the cost and acquisition time also need to be considered in deciding the source 
and detectors used. Another consideration is the layout of sources and detectors. This is usually 
decided by the object’s shape and dimension. Acquisition geometries used by breast diffuse 
optical imaging include the transmission (planar or ring shaped) or reflection mode. Based on 
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the signal used for measurement, current diffuse optical systems can be categorized into three 
major categories: systems based on the frequency-domain (FD) signal [52], direct current (DC) 
signal [53] or time-resolved (TR) signal [51, 54]. In the following part, detailed introduction 
is given on the data processing principles of FD system, which method is used in our DOT 
system. And brief introductions are given on the DC and TR systems.  
FD system 
The frequency domain system measured the re-emitted light in a broad bandwidth with the 
light source set at different frequencies. Source light intensity is modulated by AC signal at 
radiofrequency (3kHz to 300GHz) [55], and the amplitude and phase changes are measured in 
the detected signal.  
Based on the theory of diffused photon density wave [52], given a pencil beam incident 
light and semi-infinite turbid medium, the spatial energy density of diffusive wave at position 
?̅? is 
𝑈(?̅?) =
𝑆
4𝜋𝐷
[
𝑒−𝑖𝑘|?̅?−𝑟𝑠̅̅̅̅ |
|?̅?−𝑟?̅?|
−
𝑒−𝑖𝑘|?̅?−𝑟𝑖̅̅ ̅|
|?̅?−𝑟?̅?|
]    (4.1) 
Where S is the source intensity. The wave number 𝑘2 =
−𝜈𝜇𝑎+𝑖𝜔
𝐷
 and the light diffusion 
coefficient 𝐷 =
𝜈
3𝜇𝑠′
. 𝜈 is the light speed in medium and 𝜔 is the angular frequency of light. 𝑟?̅? 
and 𝑟?̅? are the real and imaginary point sources that are used as substitution for incident light. 
When the source-detector separation (ρ) is larger than the transport mean free path ztr, eq. 4.1 
can be simplified as 
𝑈(𝜌) =
𝑆
4𝜋𝐷
𝑒𝑖𝑘𝜌
𝜌2
[−2𝑖𝑘(𝑧𝑏
2 + 𝑧𝑏𝑧𝑡𝑟)]    (4.2) 
Where the extrapolated boundary position 𝑧𝑏 =
2
3𝜇𝑠
′  , and the mean free path 𝑧𝑏 =
1
𝜇𝑠
′ . 
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From eq. 4.2 we can derive the linear amplitude and phase equations, and 𝑘𝑟 and 𝑘𝑖 can be 
fitted as the slopes of amplitude (logarithmic scale) and phase versus source and detector 
distance (Fig. 4.1). 
ln(𝜌2|𝑈(𝜌)|) = −𝑘𝑖𝜌 + ln (
|𝑆|
2𝜋𝐷
[𝑧𝑏
2 + 𝑧𝑏𝑧𝑡𝑟]√𝑘𝑖
2 + 𝑘𝑟2)        (4.3) 
Φ(𝜌) = 𝑘𝑟𝜌 − 𝑡𝑎𝑛
−1(𝑘𝑟 𝑘𝑖⁄ ) + Φ𝑠𝑜𝑢𝑟𝑐𝑒       (4.4) 
 
      
Figure 4.1. Typical fitting of 𝑘𝑖 (left) and 𝑘𝑟 (right) based on the amplitude and phase 
measurements [52] 
 
The average absorption coefficient 𝜇𝑎 and the reduced scattering coefficient 𝜇𝑠
′  can thus be 
derived                        
                                                       𝜇𝑎 =
𝜔
𝜈
[tan (2𝑡𝑎𝑛−1
𝑘𝑟
𝑘𝑖
)]−1                    (4.5) 
   𝜇𝑠
′ =
𝑘𝑖
2+𝑘𝑟
2
3√𝜇𝑎+(𝜔 𝜈⁄ )2
     (4.6) 
Where 𝜔 is the modulation frequency and 𝜈 is the speed of light. Once the average measured 
µa and µs’ are determined, reconstruction is made by dividing the medium into a number of 3D 
voxels. Each voxel optical property µa(𝑟𝑣) and µs’(𝑟𝑣) of the can be decided by [52] 
                                                        𝜇𝑎(𝑟𝑣) =
∑ 𝑊(𝑟𝑠𝑣,𝑟𝑣𝑑)𝜇𝑎𝑠𝑑
∑ 𝑊(𝑟𝑠𝑣,𝑟𝑣𝑑)𝑠𝑑
         (4.7) 
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                                                        𝜇𝑠
′ (𝑟𝑣) =
∑ 𝑊(𝑟𝑠𝑣,𝑟𝑣𝑑)𝑠𝑑 𝜇𝑠
′
∑ 𝑊(𝑟𝑠𝑣,𝑟𝑣𝑑)𝑠𝑑
         (4.8) 
Where the weight matrix is computed through Green Function:  𝑊(𝑟𝑠𝑣, 𝑟𝑣𝑑) =
−𝑈0(𝑟𝑠𝑣)𝐺(𝑟𝑣𝑑)/𝐷 . 
DC system 
For these systems, only DC measurements are needed to reconstruct tissue optical images. The 
image reconstruction includes the process of solving both the forward and inverse problems. 
 In the forward problem, the diffuse equation of light in highly scattering medium is   
                                 ∇ ∙ 𝐷(𝑟)∇Φ(𝑟, 𝜔) − [𝜇𝑎(𝑟) −
𝑖𝜔
𝑐
] Φ(𝑟, 𝜔) = −𝑆(𝑟, 𝜔)                             (4.9) 
Where Φ(𝑟, 𝜔) is the photon density at position r, 𝜔 is the light modulation frequency and 
𝑆(𝑟, 𝜔) is the source term. In DC system 𝜔 is usually zero, but sometimes it is modulated at 
low frequency (e.g. kHz) to improve the SNR or to encode different sources [55]. As shown in 
Fig. 4.1, in solving the forward problem, Chen et al. used finite element  
 
Figure 4.2. Flow chart of DC system image reconstruction [53]. 
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method to get Φ𝑐𝑎𝑙   with the initial estimate of µa and D [53]. Then the difference (ΔΦ) 
between measurement Φ𝑚𝑒𝑎𝑠 and forward solution Φ𝑐𝑎𝑙 is computed minimized by iterative 
updating of µa and D. The searching step is an inverse problem and the solution is based on the 
regularization method. Here the Tikhonov regularization method was used, in which Δµa and 
ΔD can be related to ΔΦ by the Jacobian matrix (J) and regulating factor λ. 
TR system  
In the time-domain mode, temporal responses to an ultrashort laser pulse are measured around 
the measured subject to be imaged. The source light is an ultra-short pulse (in ps range), and 
the detected light pulses are broadened in terms of time. The re-emitted signal equals to the 
convolution of three functions: point spread function (PSF) due to light propagation in 
scattering medium, pulse profile of laser beam, and impulse response of the detection system 
[55]. The PSF due to light propagation in scattering medium can be solved with detected 
signals and the known source and system response, so the optical properties of the medium can 
be obtained by analytical fitting of this PSF or through iterative forward simulation. 
4.1.2 DOT for the breast tissue characterization 
Diffuse optical techniques for its utility in breast cancer diagnosis and treatment monitoring 
have been investigated extensively in the past two decades [56-63]. One critical parameter in 
breast tissue characterization is the normal tissue optical properties. The CW, FD and TR 
method have all been used to measure bulk optical properties of normal breast. Experimental 
set-ups are mainly in three positions: 1) a supine or sitting position with a hand-held probe 
placed on top of the examined breast, referred as FD reflectance or TR reflectance 
measurement [64-67]; 2) a prone position with source and detector fibers distributed around 
the examined breast, refereed as mixed CW, FD or TR reflectance and transmittance 
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measurement or ring geometry [51, 58, 68]; and 3) a prone or a standing position with the 
examined breast sandwiched between source and detector plates, referred as FD transmittance 
or TR reflectance or transmittance measurement [69-75]. Here we summarized the reported 
breast tissue bulk µa and µs’ in Table 4.1.  
Using CW method with a ring geometry, Jiang et al. measured the breast tissue background 
optical properties (µa and µs’) of three healthy volunteers and the normal breast tissue adjacent 
to a lesion of six patients.[51] The patients’ race was not found to affect measured optical 
properties. And µa and µs’ measured from breast tissue adjacent to the lesion were 0.072-0.110 
cm-1 and 7.5-10.7 cm-1, which were comparable to those from the healthy volunteers of µa = 
0.035-0.085 cm-1 and µs’ = 9.0-10.5 cm-1. Using a FD reflectance with patients in a supine 
position, Shah et al. measured breast tissue optical properties of 14 healthy subjects [64]. 
Significant difference was found between the pre- and postmenopausal subjects 
(premenopausal: µa = 0.048-0.150 cm
-1 and µs’ = 8.3-11.0 cm-1 and postmenopausal: µa = 
0.016-0.064 cm-1 and µs’ = 6.7-8.6 cm-1). Using similar technique, Cerussi et al. measured 
breast optical properties of 28 healthy subjects [65]. They found the hemoglobin, water and 
scatter power were on a decreasing trend with age for subjects older than 50. They also found 
the scatter power correlated with water concentration, and correlated negatively with lipid. 
Using a FD transmittance geometry, Durduran et al. measured the optical properties of 52 
healthy volunteers [70]. Investigation was focused on the correlation of optical properties, 
blood volume and oxygen saturation (SO2) with the body mass index (BMI) and age, and only 
a weak correlation was found between blood volume and BMI, and µs’ and BMI. By using a 
FD system with a ring geometry, Poplack and Pogue et al. first measured 11 patients and later 
23 healthy volunteers’ breasts at five wavelengths within 660-808 nm [58, 76]. The total 
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hemoglobin (tHb) and µa were found to be significantly associated with the BMI and breast 
density, but no significant association between SO2 and either BMI or breast density. Recently, 
Fang et al. measured the optical properties of 68 breasts from 49 healthy volunteers and later 
138 normal breasts from 125 subjects using a hybrid CW/FD DOT system with a transmittance 
geometry. Their study was focused on comparing the DOT measurements of hemoglobin and 
scattering maps with co-registered X-ray images of different categories of breast tissues [74, 
75]. 
By utilizing the TR reflectance method with a single wavelength and a single source and 
detector pair, Suzuki et al. studied 30 Japanese healthy volunteers and found a high correlation 
of the breast tissue µa and µs’ with age, BMI and menstrual status [69]. Later, Svensson et al. 
used a portable TR system to study water, lipid and hemoglobin concentration variation of 36 
normal subjects [66]. Their results also showed that larger source and detector separation (2 
cm vs. 1.5 cm) resulted in higher tHb and SO2 values measured. Using a similar method, Mo 
et al. measured  breast optical properties of 19 healthy Singapore women, and reported high 
correlations of tissue µa, µs’ and tHb with age, menopausal status and BMI [67]. Grosenick et 
al. developed a TR transmittance system using a single-fiber delivering and a single fiber-
bundle collecting setup to measure breast tissue optical properties of 35 patients and later 87 
patients with lesions [71, 72]. The tHb concentration and SO2 were also studied by comparing 
tumor and background tissues. Using a similar method, Spinelli et al. reported the tHb, SO2, 
lipid and water concentration from absorption spectrum of 113 measurements from both 
breasts of 150 subjects [73, 77]. Correlations of these physiological properties with age, breast 
thickness and BMI were found.   
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Table 4.1. Comparison of reported optical parameters for normal breast at NIR 
Ref. Method 
*1 
Position 
*2 
Probe 
*3  
 
N*4 
Location*5 λ 
(nm) 
µa (cm
-1) µs’ (cm
-1) 
H NC NS Mean±Std Range Mean±Std Range 
             
Shah[64] FD Supine Hand-
held 
14 14 
  
647-
956 
-- 0.016-0.150 -- 6.7-11.0 
Cerussi[65] FD Supine Hand-
held 
28 28 
  
672 -- 0.025-0.125 -- 6.8-10.5 
   
28 28 
  
800 -- 0.025-0.100 -- 6.0-9.1 
    
28 28 
  
806 -- 0.025-0.100 -- 5.8-8.7 
    
28 28 
  
852 -- 0.040-0.120 -- 5.7-8.2 
    
28 28 
  
896 -- 0.075-0.160 -- 5.5-8.0 
    
28 28 
  
913 -- 0.075-0.180 -- 5.6-7.9 
    
28 28 
  
978 -- 0.075-0.310 -- 5.4-7.8 
Svensson[66] 
 
TR Sitting Hand-
held 
36 36 
  
786 0.041±0.021 -- 8.0 ± 2.0 -- 
Mo[67] TR Sitting Hand-
held 
19 19 
  
785 0.050±0.015 -- 10.53±1.20 -- 
   
19 19 
  
808 0.052±0.015 -- 10.49±1.19 -- 
Jiang[51] CW Prone Ring 9 3 
 
6 785 -- 0.035-0.110 -- 7.5-10.7 
Poplack[58] FD Prone Ring 23 23 
  
785 0.052±0.019 0.030-0.102 11.7±2.0 7.9-15.5 
             
Suzuki[69] TR -- Plates  
-R 
30 30   753 0.046±0.014 0.024-0.078 8.9±1.3 6.3-10.8 
Durduran[70] FD Prone Plates 52 52 
  
750 0.046±0.024 -- 8.7±2.2 -- 
   
-T 52 52 
  
786 0.041±0.025 -- 8.5±2.1 -- 
    
52 52 
  
830 0.046±0.027 -- 8.3±2.0 5.0-13.5 
Grosenick[71]  TR -- Plates 28 
 
28 670 0.041±0.013 0.025-0.080 11.7±2.3 7.0-18.0 
   
-T 35 
 
35 785 0.039±0.009 0.025-0.060 10.2±1.6 6.0-14.0 
Grosenick[72] TR -- Plates 87 
 
87 670 0.036±0.008 -- 10.5±1.3 -- 
   
-T 87 
 
87 785 0.039±0.011 -- 9.5±1.4 -- 
    
8 
 
8 843 0.036±0.005 -- 8.4±0.4 -- 
    
22 
 
22 884 0.059±0.016 -- 8.0±1.0 -- 
Spinelli[73] TR -- Plates 113 
 
113 637 0.055±0.007 -- 13.4±2.6 -- 
   
-T 113 
 
113 656 0.041±0.005 -- 13.5±2.1 -- 
    
113 
 
113 683 0.042±0.013 -- 12.9±2.3 -- 
    
113 
 
113 785 0.037±0.013 -- 11.3±2.1 -- 
    
113 
 
113 912 0.110±0.021 -- 11.4±2.6 -- 
        113   113 980 0.099±0.028 -- 11.7±2.6 -- 
Fang[74] CW/FD Standing Plates  
-T 
49 49   830 -- -- 7.5±0.8 -- 
Fang[75] CW/FD Standing Plates  
-T 
125 125  830 -- -- 7.1±1.6 -- 
 
*1 Method: Measurement techniques that were used: CW: Continuous wave, FD: Frequency domain, TR: Time-
resolved. 
*2 Position: Patient position in measurement 
*3 Probe: Probe geometry for light delivery and collection. Plates: Breast is sandwiched between two plates, with 
source and detectors on the plates, T: transmission, R: reflectance. 
*4 N: Total number of subjects (healthy volunteers or patients) involved in the study.  
*5 Location: Location of the breast tissue that is measured: H:  Healthy subjects, NC: Normal breast tissue of 
contralateral reference side of the patient, NS: Surrounding breast tissue of a lesion of the same breast.  
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4.1.3 Challenges and solution 
We have developed Ultrasound (US)-guided FD-DOT technique using a hybrid hand-held 
probe for breast cancer diagnosis and treatment assessment, with the wavelengths in the range 
used by other groups summarized in Table 4.1 [62, 63, 78]. From measured light reflectance, 
lesion optical absorption maps at four optical wavelengths were reconstructed and the 
hemoglobin concentration maps of tHb, oxygenated hemoglobin (HbO2), and deoxygenated-
hemoglobin (Hb) were calculated [79]. Results have shown higher sensitivity and specificity 
in diagnosing early stage (Tis-T1) breast cancers from benign lesions [79]. Compared with the 
systems developed by other groups, our system using a hand-held probe with patients imaged 
in a supine position can be easily incorporated into a conventional US pulse-echo scanning 
with no need to adjust the probe size to fit patients’ breast. However, to probe breast lesions in 
the depth range of 1 to 4 cm, the source-to-detector separation of 3 to 8 cm is needed. At this 
range of source-to-detector separations, the chest wall affects measurements of background 
tissue optical properties [80, 81].  
We have developed several methods to minimize the chest wall effect, including a two-
layer modeling [82] and a two-layer reconstruction method [83], and a two-step fitting and 
reconstruction with a dual probe measurements (a small probe for the first layer and a larger 
probe for both layers) [84]. Despite the promising results, the clinical application of these 
methods is limited due to their intense computation and a slower convergence rate [82, 84]. 
In a recent paper, Nobuko et al. reported the effect of chest wall on light reflectance 
measurements using their TR-DOS system with 3 cm source-to-detector distance, and showed 
a function characterizing the tHb concentration in terms of chest wall depth [85]. Based on 
their measurements, they reported the tHb concentration ranging between 10-90 µM, and this 
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range reduced to 10-30 µM by taking out cases whose chest wall depths were smaller than 2 
cm.  
In this study, we have evaluated the correlation between the fitted background tissue optical 
properties and the chest wall depth from a total of 297 patients measured with our FD-DOT 
system [86]. The background optical properties were measured from the contralateral reference 
breast at the mirror position of the lesion. This is a large patient population and has diverse 
lesion types. Therefore, results should be a valuable reference for research community in DOS 
and DOT breast imaging field. An automated chest wall depth detection algorithm was 
developed by one of our lab mates, to compute the chest wall depth for each patient from co-
registered US images. The automatically detected chest wall depth was validated by an expert 
with US images. Using lesion tHb values reported in Ref. [79], we have subtracted the 
background hemoglobin level from each patient’s tHb to improve diagnosis between malignant 
and benign lesions. 
4.2 Materials and Methods 
4.2.1 Study Subjects  
A total of 297 female patients were evaluated in this study. All patients signed the informed 
consent and the study protocol was approved by local Institution Review Boards. All data 
reported in this study were de-identified according to the institution approved protocols. The 
clinical characteristics of study subjects can be found from Ref. [79].  Briefly, from the total 
300 female patients included for analysis in the referenced study, three patients were further 
excluded because digital co-registered US images were not available. Of the 297 patients 
analyzed in this study, 12 individuals without US identifiable lesions at the time of DOT study 
were considered as control group. Of the rest, 6 patients have two lesions. Thus we have total 
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291 lesions from 285 patients for analysis (the mean age is 50 years, ranging from 17 to 94 
years). Of the investigated lesions, 232 were diagnosed to be benign and 59 were malignant. 
The patients with benign lesions were further sub-categorized into 7 groups including: 
proliferative lesions (Prolif.), fibroadenoma (FA), fat necrosis and inflammatory changes (FN), 
fibrocystic changes (FC), cystic changes (Cyst), lymph node (LN), breast tissue and other 
benign categories. Among the 297 patients, 18 had US images revealing deep chest walls 
beyond 5 cm and cannot be estimated accurately. These patients were not used for analysis of 
chest wall effect on background tissue optical property measurements. 225 had disclosed their 
race (black n = 45, Asian n = 4, Hispanic n= 42 and white n = 134), of which 3 white patients 
have two measurements each at two different normal reference locations because their two 
breast lesions were at different quadrants. Thus, we have total 303 measurements from 297 
subjects analyzed for lesion diagnosis, 285 measurements from 280 subjects analyzed for chest 
wall effect, and 228 measurements from 225 subjects analyzed for skin color effect on 
reflectance measurements. 
4.2.2 US-guided DOT imaging and data processing 
The specifications of our US-guided FD-DOT system used for this group of patient data 
acquisition can be found in Ref. [79, 87]. Briefly, the co-registered US images and optical 
measurements were acquired simultaneously first from a lesion breast and then from the 
contralateral normal breast at the mirror position as the lesion (Fig. 4.3 (a)).  For each patient, 
the measurement location at lesion side was chosen that the lesion was located in the middle 
of the US image in the lateral dimension (Fig. 4.3 (c)). Four laser diodes sequentially delivered 
four optical wavelengths of 740 nm, 780 nm, 808 nm and 830 nm to the tissue and the reflected 
light was detected by 10 optical fiber bundles which coupled detected light to 10 parallel 
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photomultiplier tube (PMT) detectors. The US transducer or probe was located in the middle 
and optical source and detector fibers were surrounding the US probe. The source powers 
measured at fiber tips were: 14-18mW (740nm), 17-23 mW (780nm), 17-23 mW (808nm) and 
24-28 mW (830nm). The wavelengths 785 nm, 808 nm and 830 nm are used often in DOS and 
DOT systems (see Table 4.1) because of the need for deep tissue penetration. 740 nm provides 
more robust estimation of de-oxygenated hemoglobin in the NIR spectrum.  
The measurement procedure and geometry of the US probe and optical source and detector 
fibers is shown in Fig. 4.3 (a) and (b). The co-registered hybrid probe was placed on a lesion 
first and 4 to 6 measurements were taken. Then, the probe was placed on the contralateral 
mirror position of the lesion, which was used as reference, and 4 to 5 measurements were taken. 
Background tissue µa and µs’ were fitted from the reflectance measurements made at the 
contralateral normal breast as discussed in 4.1.1 [52]. For each wavelength, the absorption µa 
and reduced scattering coefficients µs’ are fitted by eq. 4.5-4.6. [52]. 
The average µa and µs’ obtained from 4-5 measurements made at the contralateral breast 
were used to characterize each patient’s background tissue optical properties. Reconstruction 
of an absorption (µa) map of a lesion at each wavelength is based on the Born approximation 
and conjugate gradient search for optimization [78]. The tHb map of a lesion was directly 
computed by summation of HbO2 and Hb from reconstructed µa maps  given from eq. 1.1 [4]. 
For each lesion, the average of maximum values of 4 to 6 computed tHb maps was used to 
characterize the lesion. Bulk tissue or background tissue tHb concentration was calculated from 
fitted µa values at four optical wavelengths. To minimize the chest wall effect, the lesion tHb 
was subtracted by background hemoglobin level, which represents a relative tHb concentration. 
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Figure 4.3. Measurement procedure (a) and geometry (b). (c) Typical co-registered 
ultrasound image taken at a normal breast (left) and lesion breast (right). Scale bars indicate 
1 cm.  (d) Reference measurement at 780 nm, amplitude (logarithmic scale, left) and phase 
(right) verses source and detector distance. 
 
4.2.3 Chest wall depth detection 
We defined chest wall depth as the distance from the skin to the top layer of chest wall muscle. 
An automated chest wall depth detection method was developed by one of our lab mates and 
applied to the co-registered US images. Briefly, detection of the chest wall is based on the fact 
that chest wall muscles appear as line structures in US images [88]. With that, Canny edge 
detection method was used generate the binary images, and then a Hough Transform based on 
structure segmentation using Gabor filter is applied to detect line structures. Finally, de-noising 
restrictions applied on the length, location and slope range are applied to automatically detect 
chest wall depth [89-95] .  
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In order to estimate the accuracy of this method, we measured the chest wall depth both by 
algorithm and manually by an experienced US breast imager, refereed as operator. We 
quantified the error by eq. 4.10 as: 
𝐸𝑟𝑟𝑜𝑟 =
|𝑀𝑎𝑛𝑢𝑎𝑙−𝐴𝑢𝑡𝑜|
𝑀𝑎𝑛𝑢𝑎𝑙
×100 %                                             (4.10) 
Empirically for cases with errors <15% which correspond to 2 to 4 mm for the average 
chest wall depth of 2 to 3 cm, we used automatically detected values. For cases with errors >15% 
the operator re-evaluated the chest wall depths and reassigned or confirmed the values.  
4.2.4 Evaluation of diagnostic performance 
Receiver operating characteristic (ROC) curve, as plot in Fig. 4.6, is a conventional way to 
evaluate the diagnostic performance of predictors (i.e., medical tests with positive/negative 
results) and select the optimal models in comparison with the true status of binary outcomes 
(i.e., cancer patients and non-cancer controls). ROC analysis has been widely applied in 
modern medicine, biometrics and many other fields related to diagnostic decision making. In 
statistics, a ROC curve is a graphical plot of true positive rate (TPR or sensitivity) against false 
positive rate (FPR or 1-specificity) at various threshold settings. Good prediction would yield 
a point toward the upper left corner of ROC space, and coordinate (0, 1) represents a perfect 
classification with 100% sensitivity (no false negatives) and 100% specificity (no false 
positives). The area under the curve (AUC), a summary statistics derived from ROC curve 
ranging from 0.5 to 1.0, is commonly considered as an effective measure of accuracy and a 
meaningful interpretation of ROC curve [96]. Many statistical methods have been developed 
to compare two ROCs from two diagnostic tests and evaluate statistical significance of either 
dissimilarities between two ROC curves or difference between two AUCs derived from ROC 
curves. In this study, ROC analysis was carried out by R package pROC [97], which offers a 
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helpful tool for visualizing, smoothing and comparing ROC curves, especially the paired 
design (diagnostic tests measured on same samples). The principle of ROC analysis has been 
described in the following section. 
4.2.5 Statistical Analysis  
Pearson correlation method was used to examine the correlations of the fitted µa and µs’ with 
the chest wall depth. Two-sample t-test was also performed to compare the mean difference of 
tHb between the malignant group and each benign sub-group (Table 4.4, p-values). In order to 
evaluate the diagnostic performance of tHb levels in classification of malignant and benign 
lesions, the tHb levels were used as the predictor variable and the respond variable is a binary 
corresponding to the status of tumor diagnosis based on biopsy. For analysis #1, the respond 
variable is unity for early stage malignant tumors (Tis-T1) and zero for benign lesions; For 
analysis #2, respond variable is unity for all malignant tumors including Tis-T1 and late stage 
cancers (T2-T4) and zero for benign lesions. The false positive rate (1-specificity) and true 
positive rate (sensitivity) were computed in Matlab to generate ROC curves. In each ROC plot, 
the AUC and the corresponding 95% confidence interval were calculated using R package 
pROC [97]. The statistical difference of ROCs with and without subtracting background was 
evaluated by two tests in pROC: 1) the Venkatraman’s test on two ROC curves; and 2) the 
bootstrap test on AUCs as opposed to the actual ROC curves. The Venkatraman’s method 
evaluates the integrated absolute difference between ROCs at all operating points with a test 
statistics (corresponding to statistics E in pROC), whose null distribution is generated by 
permuting the pooled ranks of two predictor variables within a study subject [98]. In our study, 
the permutation was executed for 2,000 times as a default. The Bootstrapping method tests the 
equality of AUCs for two diagnosis [97]. It defines a statistics D by dividing difference of the 
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original two AUCs with a standard deviation (s), which is the standard deviation of AUCs 
difference and is computed with 2,000 times of bootstrap replicates. In each replicate, original 
diagnostic measurements are resampled with replacement. As the statistics D follows a normal 
distribution, p-value is calculated based on observed D score. For both tests, p-value was 
computed by a two-tailed paired test and statistical significance was considered at p < 0.05.  
4.3 Results 
We compared operator manually and algorithm automatically detected chest wall depths. 
Using an error measure defined in eq. 4.10, the percentage of cases with error <15% was 67%.  
For cases with error > 15% (33%), the operator re-evaluated the chest wall depths and 
reassigned or confirmed the values. Of all cases, an average algorithm detection error was 14%, 
which corresponds to 2 to 4 mm for the average chest wall depth of 2 to 3 cm. 
We then analyzed the correlation between fitted background µa and µs’ and the chest wall 
depth of the reference side which does not have known lesions at the time of the study based 
on the evaluations of the attending radiologists from available mammograms, US, and or 
magnetic resonance imaging (MRI).  The fitted µa and µs’ at four optical wavelengths are 
correlated with the chest wall depth as shown in Fig. 4.4 and Table 4.2 with p-values less than 
0.0001. At each wavelength, the fitted µa has a much higher correlation coefficient than that of 
fitted µs’. Analysis of different races shows that as the skin color is getting lighter (the skin 
color was based on patient’s race disclosed at the time of the consent), the correlation 
coefficient between µa and the chest wall depth is higher, while the correlation between µs’ and 
the chest wall depth does not change much with skin color. This is likely caused by the deeper 
penetration of the diffused light when the skin color is lighter. There is no significant difference 
of chest wall depth between the white and black race groups and between the white and Asian  
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Figure 4.4. Fitted µa and µs’ vs. chest wall depth at different wavelengths measured at 
normal reference side. 
 
Table 4.2. Correlation coefficient (r) between fitted µa and µs’ with chest wall depth of 
entire population and different races (Total N=303, Black N=48, Asian & Hispanic 
N=50, White N=144) 
Background 
properties 
Race Chest wall 
depth (cm) 
Wavelength 
740 nm 780 nm 808 nm 830 nm 
 All Patients 2.57±0.66 0.6656 0.6733 0.6739 0.6652 
µa (cm-1) Black 2.58±0.68 0.6998 0.7164 0.7046 0.6593 
Asian & 
Hispanic 
2.49±0.70 0.6777 0.6594 0.6765 0.6596 
 White 2.53±0.62 0.7752 0.7773 0.7800 0.7803 
 All Patients 2.57±0.66 0.3311 0.3109 0.2721 0.2702 
µs’ (cm-1) Black 2.58±0.68 0.2972 0.3203 0.1975 0.2022 
Asian & 
Hispanic 
2.49±0.70 0.1746 0.2223 0.0927 0.2727 
 White 2.53±0.62 0.3845 0.3389 0.3719 0.3213 
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Table 4.3. Breast tissue bulk optical properties (Mean ± Std) measured at four optical 
wavelengths of entire population and different races (Total N=303, Black N=48, Asian & 
Hispanic N=50, White N=144) 
Background 
properties 
Race 
Chest wall 
depth (cm) 
Wavelength 
740 nm 780 nm 808 nm 830 nm 
 
All Patients 2.57±0.66 0.033±0.020 0.032±0.022 0.034±0.023 0.039±0.023 
µa (cm-1) 
Black 2.58±0.68 0.034±0.022 0.033±0.022 0.034±0.023 0.039±0.025 
Asian & 
Hispanic 
2.49±0.70 
0.035±0.020 0.036±0.025 0.039±0.027 0.042±0.027 
 White 2.53±0.62 0.033±0.020 0.032±0.022 0.034±0.022 0.039±0.022 
 
All Patients 2.57±0.66 4.5±1.3 4.1±1.2 3.7±1.1 4.6±1.1 
µs'(cm-1) 
Black 2.58±0.68 4.7±1.6 4.4±1.4 4.0±1.3 4.2±1.3 
Asian & 
Hispanic 
2.49±0.70 
4.6±1.3 4.1±1.2 3.8±1.1 4.1±1.1 
 White 2.53±0.62 4.5±1.2 4.0±1.2 3.7±1.1 4.1±1.1 
 
& Hispanic groups, however, the correlation coefficients at four wavelengths for the white 
group is significantly larger than the black (p=0.0055) and Asian & Hispanic groups 
(p=0.0001), but no significant difference was found on the correlation coefficients between the 
black and Asian & Hispanic groups (p=0.1096).  Table 4.3 shows the fitted µa and µs’ values 
of the entire population and different races. No significant difference of µa or µs’ was found 
between any two racial groups. 
We further calculated the hemoglobin concentrations from fitted bulk tissue µas at four 
wavelengths. The correlation coefficients (r) and p-values between chest wall depth and 
computed background hemoglobin values were, tHb: r = 0.6775, p < 0.0001; HbO2: r = 0.6134, 
p < 0.0001; and Hb: r = 0.6017, p < 0.0001, which are statistically significant.  
We have shown in the previous study that the lesion maximum hemoglobin concentration 
can be used to differentiate benign from malignant lesions [79]. We have investigated the 
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improvement of using this method in differentiating benign and malignant lesions by 
subtracting the corresponding background hemoglobin concentration. Fig. 4.5 shows the 
differences without and with subtraction of the corresponding background from each patient 
between malignant group (both Tis-T1 and T2-T4) and benign sub-groups of Prolif., FA, FN, 
FC, Cyst and LN. Numerical differences, standard deviations (Std) and p-values were 
computed between malignant and benign sub-groups (except for Tissue and LN group due to 
small sample sizes) and shown in Table 4.4. The error bars in Fig. 4.5 and Std values in Table 
4.4 indicate the standard deviations of the difference between malignant group and each benign 
sub-group. They were computed using the Stds and sample sizes (n) of two groups under 
comparison as Std = √
𝑆𝑡𝑑12
𝑛1
+
𝑆𝑡𝑑22
𝑛2
. An increased difference was found between the 
malignant group and 6 of the 7 benign groups in a range of 2-7 µM, except for the tissue & 
other benign group, which has a small sample size. The largest difference after subtraction was 
found from fibroadenoma (FA) due to the relative young patients with dense breast tissue and  
 
Figure 4.5. Total hemoglobin difference (ΔtHb) and Std between the malignant group (n=59) 
and benign sub-groups (Prolif. n=33, FA n=75, FN n=29, FC n=44, Cyst n=38, Tissue & other 
benign n=7 and LN n=6), and all benign group (n=232). 
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Table 4.4. Total hemoglobin differences (δ tHb), standard deviations (Std) and p-values between 
the malignant and benign tumor sub-groups with and without subtracting the background 
Subtract
-ion bg. 
Comp. 
values 
Prolif. FA FN FC Cyst 
Tissue 
& others 
LN 
Benign 
With 
ΔtHb 30.9 37.6 29.8 43.9 47.1 44.6 46.0 38.9 
Std 5.5 4.2 5.9 4.5 4.4 8.1 13.6 3.7 
p-value <0.0001 <0.0001 <0.0001 <0.0001 <0.0001 0.0004 0.0159 <0.0001 
Without 
ΔtHb 28.5 29.4 26.4 40.3 40.0 46.0 43.9 33.6 
Std 5.5 4.1 6.0 4.4 4.6 9.1 16.3 3.6 
p-value <0.0001 <0.0001 0.0001 <0.0001 <0.0001 0.0011 0.0396 <0.0001 
 
a shallower chest wall depth in this group (Mean ages are: 55±13, 41±12, 55±18, 49±12, 49±11, 
51±13 and 47±14 years for Prolif., FA, FN, FC, Cyst, tissue & other benign and LN, 
respectively). And their average chest wall depths were: 2.64±0.54, 2.44±0.75, 2.53±0.70, 
2.59±0.72, 2.42±0.62, 2.71±0.48 and 2.49±0.67 cm, respectively.  
The ROC curves (sensitivity vs. 1-specificity) using a threshold of tHb level for predicting 
early stage malignant lesions (Tis-T1) and all malignant lesions (Tis-T1 and T2-T4) from the 
benign cases are given in Fig. 4.6. 64 µM was chosen as the optimal threshold for diagnosis 
using relative lesion tHb after subtracting the background values, and 80 µM was used for 
diagnosis without subtracting background values. We compared both ROCs and AUCs in R 
package pROC [97] using tHb levels before and after subtracting the background. When 
comparing the ROC curve after background subtraction against the one before subtraction, we 
obtained p = 0.0025 for Tis-T1 diagnosis and p = 0.1010 for all malignant lesion diagnosis.  
As shown in Fig. 4.6, we observed a significantly higher AUC for Tis-T1 diagnosis with an 
increased AUC of 3.0% (p = 0.0016) and all malignant lesion diagnosis with an increased AUC  
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                                             (a)                                                                      (b) 
Figure 4.6. ROC curve (a) Tis-T1 vs. benign cases and (b) Tis-T1 and T2-T4 vs. benign 
cases. 
 
Table 4.5. Sensitivity, Specificity, Positive predictive value (PPV) and Negative Predictive 
Value (NPV) of tHb before (th=80 µM) and after (th=64 µM) subtracting background value 
Subtraction 
bg. 
Parameter Sensitivity Specificity PPV NPV 
 
 
With Tis-T1 87.5 % 92.6 % 66.0 % 97.8 % 
Tis-T1 and T2-T4 74.6 % 92.6 % 71.0 % 93.8 % 
Without Tis-T1 85.0 % 90.2 % 58.6 % 97.4 % 
Tis-T1 and T2-T4 72.9 % 90.2 % 64.2 % 93.2% 
 
of 2.8% (p = 0.0159). These results have demonstrated that background subtraction method 
has consistently improved diagnostic performance for early breast lesions.  
Table 4.5 shows the sensitivity, specificity, positive predictive value (PPVs) and negative 
predictive value (NPVs) in diagnosing malignant tumor from the benign lesions using tHb data 
with and without subtracting the background data. Results show an improvement of 1.7-2.5% 
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in sensitivity and specificity, 6.8-7.4% improvement in PPV and around 0.4-0.6% 
improvement in NPV after subtracting the background values.  
4.4 Discussion  
The fitted µa and µs’ measured in the reflection geometry using larger source and detector 
separations are not true representation of tissue background optical properties due to the 
influence of chest wall underneath the breast tissue. This suggests that diagnosis between 
malignant and benign lesions is best performed by using relative hemoglobin concentrations 
after subtracting corresponding background values computed from fitted µas at multiple optical 
wavelengths. Another advantage of using relative hemoglobin values for diagnosis is that this 
method eliminates the effect due to hemoglobin level fluctuations in certain type of patients 
who may be under anemia or some drug effect. For those patients, the background blood 
hemoglobin concentration differs significantly from the normal values. Skin color does affect 
the light penetration and therefore the fitted background values from dark skin color patients 
are less affected by the chest wall depth. We understood that there is individual difference of 
skin color from each race group, however, our assumption that the skin color order from dark 
to light: black>Asian & Hispanic>white, was based on the general trend and our result shows 
an agreement with this trend. The Asian & Hispanic group has a mixed skin color, and no 
significant difference on the correlation of fitted µa with chest wall depth was found compared 
with the black group. The sample size of each group is large and it should not affect reported 
results. As shown in Table 4.3, the fitted µa and µs’ for the three groups are very similar. 
For each patient, we typically collect 4 to 6 sets of measurements from the contralateral 
breast at slightly different locations. The separation between each set of measurements varies 
from few seconds to tens of seconds because of hand-held operation. The fitted background 
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tHb of each patient is the average of these 4 to 6 data sets. In general, the fitted tHbs for each 
patient are very close with average standard deviation of 2.0 µM. 
The relative tHb computed with reconstructed µa was used as the predictor for generating 
ROC curves for the study. When comparing the closeness of two ROC curves with and without 
background subtraction by the Venkatraman’s method in R package pROC, we observed a 
statistically different ROC curves for Tis-T1 diagnosis (p = 0.0025) but similar ROC curves 
for all malignant lesion diagnosis (p = 0.1010). Consistent with this, the background 
subtraction method yielded a statistically higher AUC for Tis-T1 diagnosis (p = 0.0016, Fig. 
4.6a). However, we also obtained a higher AUC for all malignant lesion diagnosis (p = 0.0159, 
Fig. 4.6b).  The inconsistent result is likely due to differential statistics employed in two 
different ROC tests. As can be seen in either case of Fig. 4.6, the 95% CIs of two AUCs with 
and without subtracting background overlap with each other. In general, if confidence intervals 
do not overlap, it suggests a significant conclusion, however the reverse is not always true and 
our data might be this case. Given the observed difference of two AUCs (Tis-T1 diagnosis: 
3%; all malignant lesion diagnosis: 2.8%), the 2,000 times of bootstrap resampling method 
generated small empirical standard deviations, for Tis-T1 diagnosis and for all malignant cases, 
resulting in large D values and significant p-values accordingly. Nevertheless, improvement 
of our subtracting method for all malignant lesion diagnosis can only be considered as marginal 
and needs to be confirmed by future studies. 
We also studied the distribution of tHb versus age, and found the trend was generally in 
agreement with that reported by Cerussi et al [65]. However, our data were more scattered than 
the results reported in this paper. The chest wall effect still played a role on our data even we 
selected measurements with the chest wall depth deeper than 2 cm. Moreover, as shown in 
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Table 4.1, the measured µa is in the range of 0.025-0.110 cm
-1 and µs’ in the range of 5.0-15.5 
cm-1, while our measured µa is in the range of 0.0001-0.130cm
-1 and µs’ in the range of 0.6-8.4 
cm-1. Although µa is similar to the reported values, µs’ is lower. The tHb values were measured 
to be in the range of 1-58 µM, which is similar to the range of 0-60 µM reported in Ref. [65], 
and lower than the range of 10-90 µM reported in Ref. [99]. 
In the past, we also tried to remove the chest wall effect by using shorter source-detector 
measurements [80, 82-84]. Results show that although correlation coefficient was smaller 
when shorter source-detector measurements were selected, the fitted µa was still correlated with 
the chest wall depth but not µs’ for the source and detector range we have.  
4.5 Conclusion 
This chapter reviewed breast tissue optical properties measured by diffuse optical spectroscopy 
or tomography techniques. Our measurements from 297 patients show significant correlation 
between the measured optical properties and the chest wall depth even the background µa were 
similar to those reported in the literature. By subtracting background tHb computed from fitted 
background µas of all wavelengths, the relative tHb improves sensitivity, specificity, positive 
and negative predictive values in breast cancer diagnosis. 
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Chapter 5 Hemoglobin optical phantom 
5.1 Introduction 
5.1.1 Tissue mimicking phantom 
In our previous studies, we generally used 0.8% intralipid solution as a phantom mimicking 
the optical properties of background normal breast tissue for calibrating the DOT system. Since 
the aqueous suspension is not easy to handle with and need to be prepared every time before 
experiment, we started to make a solid phantom with the RTV (room temperature vulcanization 
silicone) silicon rubber, whose preparation procedures is described in Appendix II.  
    In order to simulate the diseased tissue (the target, i.e. tumor) embedded in normal 
background, we first used different sized and different contrast spherical balls (phantoms made 
in our lab by materials calibrated with DOT system) and then cubes (made with ink, TiO2 and 
RTV materials), whose absorption at the NIR wavelength range were made to be close to 0.1 
cm-1 and 0.2 cm-1. But these phantoms cannot be used to simulate the SO2 property of diseased 
tissue. Later for the evaluation of SO2 measurement accuracy by our DOT system, we made a 
hemoglobin filled glass ball phantom to closely mimic the enriched blood supply in the tumor. 
The oxygen saturation can be carefully manipulated to be close to 100% and 0% for the 
measurement. 
5.1.2 Hemoglobin  
Hemoglobin (Hb) is the main absorber in blood (Fig. 5.1). It also functions in transporting the 
oxygen in the human body. The combination of Hb with oxygen or other molecules (such as 
CO or CO2) changes its absorption spectrum in both visible and near infrared (Fig. 5.2) 
wavelength range. Therefore, by measuring the multi-wavelength absorption map with a DOT 
system, it is possible to monitor the SO2, which equals to the percent of HbO2 over tHb, in the 
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investigated tissue in vivo. In order to estimate the accuracy of the measurement by DOT 
system and also to calibrate the system, making a phantom that mimic the blood optical 
properties with known SO2 levels and time-stable properties is in need. 
  In selecting hemoglobin product that can be used for making a phantom, the absorption 
spectrum of hemoglobin from human and animal is of little difference. However, the ferrous 
state hemoglobin (with Fe2+ in the center of the heme, Fig. 5.1) is easily transformed into the 
methemoglobin in the air, which is the ferric state (Fe3+) and lose its combining capability to 
O2, whose extinction coefficient spectrum gradually changes to the methemoglobin one shwon 
in Fig. 5.2. An empirical estimation of the speed of this process is that approximately 1% HbO2 
changes into methemoglobin per day at about 0°C in liquid solution. Therefore, it is critical to 
avoid or reduce contact of hemoglobin with the omnipresent oxygen in air in storing and in 
making a phantom.  
         
Figure 5.1. Molecular structure of the heme in hemoglobin [104]  
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Figure 5.2. Extinction coefficient of different state of Hb [105] 
 
5.1.3 Deoxygenation of hemoglobin 
At the beginning of this study, three methods were considered for launching the deoxygenation 
process: by pumping nitrogen gas [100], by adding yeast and then pumping nitrogen gas [101], 
or by adding sodium dithionite (Na2S2O4) [102]. We have tried with all three methods. 
Unfortunately, the first and second methods was not seen as apparent effective. The third 
method was observed to deoxygenate the hemoglobin solution quickly, but the deoxygenated 
hemoglobin was not stable and can change within minutes. According to literature, releasing 
of O2 by blood hemoglobin after mixing with Na2S2O4 was found and studied for long [102]. 
The reaction is fast and product is not stable as it is quickly re-oxygenated probably, possibly 
resulted from the reaction of some side-products from the initial reduction. The reductive half-
time is not linear with Na2S2O4 concentration. For blood cells, when the concentration 
increases to around 25 mM, the O2 releasing half-time is approaching flat [102].  
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5.2 Materials and methods 
For later phantom experiment, as Instrumentation Laboratory provides standard Hb solution 
with the tHb concentration similar to that of human and known SO2 [103], we used this type 
(Multi-4, Level 2, Instrumentation Laboratory, MA) as the initial HbO2 sample and material 
for making the deoxygenated Hb sample. According to the specifications provided by company, 
for Multi-4, Level 2 product the hemoglobin concentration is: tHb=138 g/L, and HbO2 is 
around 96.6%. 
 We used the UV-Vis spectrometer (Varian Cary®, Agilent, US) and disposable cuvette for 
the calibration of hemoglobin concentration and SO2. After that, a series of tests using the DOT 
system were made. For each measurement, we filled a thin wall glass ball (thickness ~0.1 cm) 
with diluted HbO2 or Hb solution, sealed the ball neck with hot glue and connected the ball 
with clear glass fibers. The ball and fiber are then fixed to the clay attaching to the bottom of 
the container. The aqueous background matrix was then filled in the container and during 
experiment, the DOT probe surface is immersed in the background matrix and can be adjusted 
up and down to acquire data with probe-to-target-top distance varying between 1 to 3 cm, with 
0.5 cm step increments. The background matrix was prepared with different concentration of 
intralipid in water.  
During the experiment, we followed three steps of measurement: First, we tested with 
target filled by different hemoglobin concentration solutions (100 and 180 µM) with 
background medium (background II, 0.8% intralipid by volume, and µa=0.02-0.03 cm
-1 and 
µs’=8-9 cm-1). We measured with different sized glass balls (d=2.0 cm, 2.4 cm and 2.8 cm) 
and at various depths (1.5 cm, 2.0 cm, 2.5 cm, 3.0 cm and 3.5 cm). Secondly, we changed the 
background properties to µa=0.005-0.02 cm
-1, µs’=3-4 cm-1 (background I, 0.4% intralipid) and  
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Figure 5.3. (a) Glass ball filled with HbO2 solution and connected to holding fibers, and (b) 
Sketch of the testing experimental setup. 
 
µa=0.02-0.03 cm
-1, µs’=11-12 cm-1 (background III, 1.2% intralipid) and repeated previous 
procedures. Third, we acquired DOT data at 180 µM HbO2 and Hb solution and with 
background II. The procedures in preparing Hb solution can be referred to Appendix IV. We 
then computed the SO2 with different wavelength measurements at 740 nm, 780 nm, 808 nm 
and 830 nm and compared with calibrated values by the spectrometer. 
DOT images are reconstructed from measured data and the maximum reconstructed µa will 
be compared with the calibrated values. The HbO2 and Hb concentrations are computed with 
method described in part 1.4 using reconstructed peak absorption coefficients at 740, 780, 808 
and 830 nm. When computing the SO2 for some HbO2 samples, the results are slightly higher 
than 100%, and we assume this is due to computation error and correct them as 100% in later 
results description. We tested the target SO2 with different glass ball sizes, different depths, 
different backgrounds and different calibrated SO2 (0% and 100%).   
5.3 Results 
5.3.1 Calibration result 
The calibration results (spectra and computed SO2) measured with the UV-Vis spectrometer 
are displayed in Fig. 5.6 and Table 5.4. Fig. 5.6 show the plots of average spectra of oxygenated 
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and de-oxygenated Hb solutions generated and measured 5 times at 180 µM concentration. Hb 
solution was generated by adding 50 mg Na2S2O4 to the 4 ml solution (resulting in 72 mM 
concentration). The calculated SO2 for each measurement are listed in Table 5.4.  
5.3.2 Results of different concentration, different size, different background medium 
With the HbO2 solution diluted at 100 and 180 µM, the measured and reconstructed µas are 
shown in Table 5.1, and the SO2 from 3 cm target depth measurements (from the result at these 
concentrations measurements at 3-3.5 cm are more accurate) are shown in Table 5.2. 
Theoretically, the SO2 for this solution should be 96-100%, as indicated by the product 
specification and it should not decrease in short time with air presence.  
Table 5.1. Reconstructed µa measured at 100 µM and 180 µM 
Target 
diameter (cm) 
λ (nm) Background I Background II Background III 
100 
µM 
180 
µM 
100 
µM 
180 
µM 
100 
µM 
180 
µM 
2.0 740 0.020 0.027 0.035 0.039 0.045 0.048 
780 0.041 0.064 0.053 0.064 0.063 0.068 
808 0.050 0.078 0.062 0.073 0.081 0.081 
830 0.061 0.107 0.074 0.091 0.091 0.080 
2.4 740 0.019 0.026 0.054 0.040 0.045 0.050 
780 0.045 0.065 0.068 0.082 0.065 0.088 
808 0.048 0.082 0.064 0.095 0.062 0.106 
830 0.060 0.137 0.086 0.110 0.058 0.114 
2.8 740 0.020 0.026 0.038 0.043 0.039 0.061 
780 0.041 0.047 0.056 0.085 0.068 0.080 
808 0.045 0.065 0.059 0.096 0.084 0.078 
830 0.063 0.098 0.070 0.111 0.075 0.085 
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Table 5.2. SO2 (%) measured at 100 µM and 180 µM 
Target diameter 
(cm) 
Background I Background II Background III 
100 µM 180 µM 100 µM 180 µM 100 µM 180 µM 
2.0 100 100 92 97 93 82 
2.4 100 100 71 100 62 93 
2.8 100 100 83 100 90 66 
 
 The parameters set in processing the data are: For 2.0 cm diameter target, fine mesh x, y 
and z axis radius are set as 2.7 cm, 2.7 cm and 0.89 cm. For 2.4 cm diameter target, these are 
set as 3.3 cm, 3.3 cm and 1.09 cm. For 2.8 cm diameter target, these are set as 3.9 cm, 3.9 cm 
and 1.29 cm. The fine mesh pixel resolution is 0.25 cm in x and y axis, and 0.5 cm in z axis. 
The course mesh size is 9×9×3.5 cm in x, y and z axis, and its resolution is 1.5 cm in x and y 
axis, and 1 cm in z axis. In reconstruction, the target centers are slightly moved around to make 
the peak value to be close to fine mesh area center. 
From the DOT result, although the reconstructed µa is much smaller than the theoretical 
values (for 100µM HbO2 at 780 nm: theoretical µa = 0.164 /cm, with calculation procedures 
shown in Appendix III, and the calibrated results shown in Fig. 5.6; And for HbO2 180 µM at 
780 nm: theoretical µa = 0.294 /cm), the reconstructed values at different conditions show some 
trends: Target with 180 µM hemoglobin solution shows more accurate measured SO2 result. 
At these concentrations, deeper target depth (3-3.5 cm) results in more accurate SO2 result. 
Reconstructed µa are generally higher for stronger scattered background medium (background 
III), but the measured SO2 is more accurate at less scattered medium (background I). The target 
size is not shown to have significant effect on the reconstructed value.  
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5.3.3 Oxy-Hb and deoxy-Hb measurement 
As a result of the change of spectra after Na2S2O4 is added, a visible color change of the 
solution is also shown (Fig. 5.4). Calibrated absorbance spectra measured by the UV-Vis 
spectrometer is shown in Fig. 5.6. And the measured absorption coefficients at 740, 780, 808 
and 830 nm with the DOT system with target at 3 cm depth are shown in Fig. 5.5. Both are the 
average of measurements of 5 times. Note a difference of cross-point exists in the HbO2 and 
Hb sample spectra between the DOT and spectrometer measurement. 
 
 
Figure 5.4. Photo of glass ball (2 cm) filled with hemoglobin samples 
 
 
Figure 5.5. µa of hemoglobin samples measured with DOT system 
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Figure 5.6. Absorbance of hemoglobin samples measured with spectrometer 
 
Table 5 3. SO2 (%) computed from the DOT measured data 
Solution\Depth 1.5 cm 2 cm 2.5 cm 3 cm 
HbO2_1 45 48 77 96 
HbO2_2 30 44 68 98 
HbO2_3 44 75 64 93 
HbO2_4 77 76 71 97 
HbO2_5 36 49 75 94 
Hb_1 82 93 22 21 
Hb_2 59 85 32 26 
Hb_3 52 68 45 26 
Hb_4 67 83 33 28 
Hb_5 49 76 41 27 
 
Table 5.4. SO2 (%) computed from the spectrometer measured data 
HbO2 97.8 97.5 97.4 96.7 97.3 
Hb 6.6 5.3 13.4 6.0 4.3 
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The computed SO2 from spectra are listed in Table 5.3 and 5.4. From the DOT data (Table 
5.3), measurement with target at 3 cm depth gives more accurate SO2 result, same as in 5.3.2. 
And by comparing DOT measurements with the calibrated data (Table 5.4), the SO2 values 
measured from two systems with the HbO2 sample are consistent, but measured SO2 values of 
Hb sample by DOT system are ~20% higher than those measured by the spectrometer. 
5.4 Discussion  
In this study, the reconstructed µa from DOT data is much lower than the theoretical and 
calibrated values. We concede that the reflection due to thin wall of glass ball contributed a 
little on the error. Major part of this error should come from parameters setting for 
reconstruction, as reducing the fine mesh dimension and enlarging the fine voxel size leads to 
an overall higher reconstructed µa. In processing this study results, I used similar parameters 
setting that was used for processing clinical data. In order to get accurate reconstructed µa, this 
needs to be adjusted. However, the trend given by current results should not change, as same 
parameters are used for reconstruction at all cases for evaluating the effect of different target 
size, different target contrast and different background property. 
From Fig. 5.6, the average measured spectrum of Hb sample was raised up significantly 
comparing that of the HbO2 sample. This causes the moving of cross-point between the HbO2 
and Hb spectra at the same concentration (theoretically they should have cross point at ~800 
nm).  It can be explained as the result from increased scattering coefficients after adding 
Na2S2O4. Since reflected signal is measured in DOT system and transmitted signal measured 
in the UV-Vis spectrometer, it results in decreased absorption measurements by DOT system, 
and increased absorbance measurements by the spectrometer. 
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Table 5.3 and 5.4 also show measured SO2 difference between DOT data and the 
spectrometer measured data. The major reason should be operative timing difference. For 
spectrometer measurement, we used the cuvette as the hemoglobin container and can seal it 
with a stopper in seconds then measure immediately after adding Na2S2O4. For DOT 
measurement, we injected sample into the glass ball with a syringe, sealed the ball with hot 
glue, fixed it into the intralipid by clay and fiber, adjusted the probe position and then started 
to measure. As the re-oxygenation of de-oxygenated hemoglobin after adding Na2S2O4 occurs 
within minutes, we manipulated the temperature carefully to slow this process. We assumed 
and saw from the results that a low temperature slows the de-oxygenation process, and after 
the mixed solution being isolated from air, incubation at warm environment accelerates the de-
oxygenation reaction and later re-oxygenation is retarded due to the isolation. This can be seen 
from Appendix IV calibration result, that after adding Na2S2O4 and glass ball sealing, longer 
incubation time shows better results.  
5.5 Conclusion 
In summary, from this group of hemoglobin measurements, target with 180 µM HbO2 solution 
shows more accurate measured SO2. At 100 µM and 80 µM concentrations, measured SO2 is 
better discernable and more stable when the target depth is at around 3 cm. Reconstructed µa 
are generally higher for more scattered background medium, but measured SO2 is more 
accurate at less scattered medium. DOT system is confirmed to be able to measure HbO2 and 
Hb sample with comparable results to the spectrometer ones.  
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Chapter 6. Summary and future works 
6.1 Tumor hypoxia dyes 
Tumor hypoxia is an important tumor microenvironment and targeting tumor hypoxia is 
significant in predicting tumor response to treatments. We did a series of in vitro, in vivo and 
ex vivo experiment and illustrated improved performance of the third generation hypoxia-
targeting rigid dye in labeling mice tumor. The stained areas by our dye correlate with those 
stained by the commercial hypoxyprobeTM-1. Further studies also showed the 4-
nitroimidazole-ICG retained to a great extent in hypoxic tumors when compared with the 
second generation piperazine-2-nitroimidazole ICG.  
 Currently we are moving toward the understanding about the mechanism of our dyes 
staying more in the tumor, liver and kidney. Promising results have shown some protein(s) 
from the tumor extract that are bound by our dyes were found on the SDS-PAGE gel. Further 
experiment will be done in separating and purifying these protein(s) by using the biotin-avidin 
reaction and in obtaining the exact molecular structure of the protein(s). The toxicity of our 2-
nitroimidazole dyes should also be investigated.  
6.2 DOT breast cancer diagnosis 
We analyzed the chest wall effect on the breast DOT data from 297 patients, and tested the 
effect of applying a direct subtracting method on reducing the chest wall effect. Results show 
solid improved prediction values in using the measured ΔtHb to detect early malignant tumor 
from investigated tumor lesions. Moreover, from the results we also found the chest wall effect 
on patient data with different skin colors is different. Despite the chest wall effect, a decreasing 
trend of hemoglobin values were shown with older ages of the patient. Lastly, a hemoglobin 
phantom that mimics the oxygen saturation property (0% and 100%) of breast lesion is made 
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and tested. Later study should towards the evaluation of adjusted reconstructing parameters 
setting on the accuracy of measured target properties (µa and SO2). The property measurement 
error is also shown to be different at different depths. This problem is under investigation by 
one of our lab mates. A depth compensation algorithm or lookup table is to be developed for 
getting more similar reconstructed values at all depths.  
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Appendix I. Three generations of dye-conjugates and their molecular structures 
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Appendix II. Procedures used for making solid breast tissue phantom 
Materials: RTV silicone base, hardener, Titanium dioxide (TiO2), Indian ink 
Procedures: 
1. Weigh 1 kg RTV silicone base; 
2. Weigh 31 g hardener; 
3. Weight 0.6 g TiO2; 
4. Get 5.5 µl Indian ink with pipette and dilute with 70 µl H2O; 
4. Add the TiO2 and diluted Indian ink into hardener, and stir well with a mixer; 
5. Sonicate the mixture for 10 min; 
6. Stir again with the mixer; 
6. Add the mixture into RTV silicone base and stir for 20 min; 
7. Take 3 rounds of vacuuming and stirring procedures, each with 10 min; 
8. Pour the mixture into a container and placed under vacuum overnight. It will become dry in 
the room temperature. 
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Appendix III. Hemoglobin concentration calculation 
Suppose original hemoglobin solution concentration is: 
tHb = 138 g/L 
For hemoglobin: (http://omlc.org/spectra/hemoglobin/) 
MW (molecule weight) = 64,500 g/mole 
 So, the concentration in molar is:  
c = 138 g/L / 64,500 g/mole = 2.1 mM 
The ampule has 1.7 ml hemoglobin solution. Suppose one can get 1.5 ml from it (it's hard to 
get all of them), then in order to prepare all the concentrations it can be diluted to: 
180 µM: V = 1.5 mL × 2.1 mM / 180 µM = 17.5 mL 
100 µM: V = 1.5 mL × 2.1 mM / 100 µM = 31.5 mL 
The absorption coefficient (µa) can be calculated as (also referred to 
http://omlc.org/spectra/hemoglobin/) : 
µa (λ) = 2.303 × ɛ(λ) × c 
For example, for 100 µM HbO2 the absorption coefficient at 780 nm can be calculated: 
µa = 2.303 × 710 /cm/M × 100×10
-6 M = 0.164 / cm 
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Appendix IV. Deoxy-Hb solution preparation procedures 
The de-oxygenated hemoglobin (Hb) solution is prepared by adding Na2S2O4 solution into the 
diluted oxygenated hemoglobin (HbO2). Below are the procedures for making 180 µM HbO2 
and Hb solutions. 
Materials: Human purified hemoglobin solution, purified water, Na2S2O4, dry ice, glass ball, 
hot glue. 
Procedures: 
1. Dilute original solution with purified H2O to solution A: 1.5 ml->15 ml; 
2. Prepare 180 µM HbO2 and Hb solutions 
• For HbO2 solution, 3.5 ml solution A + 0.5 ml purified H2O; 
• For Hb solution, 3.5 ml solution A + 0.5 ml purified H2O with 50 mg Na2S2O4; 
• For Hb solution, mix at temperature ~0 °C (on top of dry ice, when the solution is close 
to be frozen); 
3. Fill the solution into 2 cm glass ball, and seal the ball quickly with hot glue; 
4. Incubate at ~37 °C for 6 min; 
5. Setup the ball and probe in intralipid and start to measure. Finish measurement in less than 
10 min.  
Notes: 
1. For Hb measurement, make sure the intralipid is cold to 0-5 °C (can use dry ice); 
2. As a calibration, the SO2 of Hb solution measured by spectrometer decreased along 6 min 
incubation after adding Na2S2O4. The values are listed below. 
 
